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Introduction  
Psoriasis is a chronic immune-mediated skin disease that affects people of all ages and 
both genders equally. It has been calculated that between 1% and 2% of the world 
population suffers from psoriasis. Of those affected, approximately 10% suffer from 
severe forms of psoriasis. Traditionally, therapeutic options for treating moderate-to-
severe psoriasis have been limited. Three of the so-called “non-biological systemic 
therapies” (i.e. acitretin, ciclosporine, and methotrexate) are the most commonly used 
systemic drugs worldwide. Biological drugs have been authorised for use in moderate 
and severe forms of psoriasis, e.g. tumor necrosis factor (TNF) antagonists (e.g. 
infliximab, etanercept, and adalimumab), antagonist of interleukin (IL)-12/23 (e.g. 
ustekinumab), and anti-IL-17 (e.g. secukinumab and ixekizumab). Recently, a new oral 
non-biological phosphodiesterase inhibitor (apremilast) has also been approved for the 
treatment of psoriasis. However, there are long-term safety concerns, as well as 
uncertainties about the effectiveness in daily clinical practice and for patients who have 
different characteristics to those recruited in randomised clinical trials, which need to be 
answered. Since approval of the first anti-TNF for the treatment of moderate-to-severe 
chronic plaque psoriasis, several registries have been established that seek to assess the 
long-term safety of biological drugs. In Spain, the BIOBADADERM registry was 
established in 2008 with this aim. 
 
Objectives: 
• To describe the infections that occurred in patients who received biological drugs 
and those who received non-biological systemic drugs from the Spanish registry of 
systemic therapy of psoriasis (BIOBADADERM) and to compare the risk of 
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infections, risk of serious infections, and risk of infection recurrences for each of the 
different biological and non-biological drugs with that of the methotrexate control 
for confounding factors and to evaluate changes in the rate of overall infection 
during the study period.  
• To describe and compare drug survival with different biological (e.g. infliximab, 
etanercept, adalimumab, and ustekinumab) and classic (e.g. methotrexate and 
acitretin) systemic agents to treat psoriasis using data from the BIOBADADERM 
registry, to check survival analysis values to measure safety, and to critically 
describe which factors influence the survival analysis in psoriasis. 
• To describe and compare the baseline demographics and clinical characteristics of 
patients being treated with classic and biological systemic therapies in the 
participating registries in Psonet network, which is an international network of 
different psoriasis registries. 
 
Materials and Methods 
For the studies in the present thesis, data from the BIOBADADERM registry and 
Psonet network were used. 
BIOBADADERM is the Spanish registry of systemic therapy in psoriasis and involves 
a multicentre, prospective cohort study in clinical practice with 12 dermatology 
departments across Spain that have been participating since 2008.  
Psonet is an international network of independent national registries that aims to 
document “real-life” use of systemic drugs for psoriasis in different countries and is 
designed to combine data from multiple international independent psoriasis registries. 
The goals of Psonet include providing estimates of the safety of these treatments in 
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long-term use and describing differences among countries in the use of biological and 
classic systemic therapies. 
 
Results 
Article 1. Infections in moderate-to-severe psoriasis patients treated with biological 
drugs compared to classic systemic drugs: findings from the BIOBADADERM 
registry 
Background: Information regarding the safety of biological drugs prescribed to 
psoriasis patients on daily and long-term bases is insufficient.  
Methods: Data from the BIOBADADERM registry (Spanish Registry of Adverse 
Events for Biological Therapy in Dermatological Diseases) was applied to generate 
crude rates of infection during therapy with systemic drugs, including biological drugs 
(e.g. infliximab, etanercept, adalimumab, and ustekinumab) and non-biological drugs 
(e.g. acitretin, ciclosporine, and methotrexate). The unadjusted and adjusted risk ratios 
(RRs) (with propensity score adjustment) of infections, serious infections, and recurrent 
infections from systemic therapies compared to methotrexate using Poisson regression 
were also calculated.  
Results: Our study included records of 2,153 patients (7,867.5 person-years). The 
adjusted RR of the overall infection was significantly higher in the groups treated with 
adalimumab combined with methotrexate (adjusted RR = 2.13, 95% confidence interval 
[CI] = 1.2–3.7), infliximab (adjusted RR = 1.71, 95% CI = 1.1–2.65), ciclosporine 
(adjusted RR = 1.58, 95% CI = 1.17–2.15), ustekinumab combined with methotrexate 
(adjusted RR = 1.56, 95% CI = 1.08–2.25), and etanercept (adjusted RR = 1.34, 95% CI 
= 1.02–1.76) than those treated with methotrexate alone. Ciclosporine had a significant 
risk of serious infection (adjusted RR = 3.12, 95% CI = 1.1–8.8), followed by 
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adalimumab combined with methotrexate (adjusted RR = 3.28, 95% CI = 0.8–13.5). 
Adalimumab in combination with methotrexate had the highest risk of infection 
recurrence (adjusted RR = 4.33, 95% CI = 2.27–8.24). 
Conclusion: Only acitretin had a significantly lower adjusted risk than that of 
methotrexate, with methotrexate considered a reference for safety in terms of infections. 
More data are required regarding the safety of combining biological drugs 
and methotrexate in psoriasis patients. Finally, the study showed no significant change 
over time in the incidence rate of infections between patients taking methotrexate and 
patients taking other drugs or drug combinations. 
 
Article 2. Survival of patients from the use of classic and biological systemic drugs 
in psoriasis: results from the BIOBADADERM registry and critical analysis  
Background: Few reported studies have compared drug survival of patients with 
moderate-to-severe psoriasis. 
Objectives: To describe and compare the drug survival of patients receiving systemic 
drugs, including biological agents (e.g. infliximab, etanercept, adalimumab, and 
ustekinumab) and classic drugs (e.g. acitretin, ciclosporin, and methotrexate), for 
moderate-to-severe psoriasis. 
Methods: This was a multicentre, prospective, cohort study of patients receiving 
systemic therapies between 2008 and 2013 in 12 hospitals in Spain. Baseline data and 
drug discontinuations were collected. Drug survival presented in Kaplan–Meier survival 
curves. We compared adjusted RRs of serious adverse events with survival analysis 
results of adverse events. 
Results: A total of 1,956 patients were included in the analysis (1,240 exposed to 
biological therapies during follow-up and 1,076 to classic therapies). The median 
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follow-up time was 3.3 years (0.0–5.1 years). There were 2,209 discontinuations out of 
3,640 therapy cycles started. The main reason for discontinuation was a lack of efficacy 
(36.4%) and remission (27.2%). Biological therapies showed a higher drug survival 
than that of classic therapies and the pattern of survival results for all outcomes 
(positive or negative) were similar. Adjusted RRs of serious adverse events did not 
agree with the survival analysis results. 
Limitation: A limitation of the study was that it was an observational study with 
potential selection bias. 
Conclusion: Survival as a proxy measure of drug safety in psoriasis is inadequate. 
 
Article 3. Drug survival analysis is not a good method for assessing the safety or 
effectiveness of systemic therapies in psoriasis 
There is a growing number of publications describing the survival of patients receiving 
systemic treatments for moderate-to-severe psoriasis. This concept has been applied in 
various chronic diseases as a proxy for the overall effectiveness of a therapy, given the 
association of survival with efficacy, side effects, and patient satisfaction. Because drug 
survival is associated with many variables, however, it is difficult to interpret. 
Comparisons between different studies or different drugs are generally impossible, and 
many discrepant findings have been generated.  
In the present article, we discuss several issues and limitations of survival analysis 
studies in psoriasis that highlight why drug survival studies do not offer the best method 
for evaluating the safety or effectiveness of psoriasis treatments, and that they are 
particularly inappropriate for comparing treatments. In a recent study that utilised 
BIOBADADERM registry data (Article 2), drug survival used as a proxy indicator of 
safety was found to be misleading.  
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Therefore, the best way to measure safety is to publish the rates of adverse events in 
cohort studies. Effectiveness is best demonstrated via experimental or observational 
studies in which effectiveness is specified as the outcome measure. Drug survival 
analysis, with all its inherent problems, might be of interest mainly for generating 
models to assess treatment cost. 
 
Article 4. Factors associated with receiving biological or classic systemic therapy 
for moderate-to-severe psoriasis: evidence from the Psonet registry.  
background: The Psonet network combines data from international psoriasis registries 
to assess the use and safety of systemic therapies to treat psoriasis. We documented 
heterogeneity in the use of systemic therapies among countries.  
Objectives: To describe and compare the characteristics of patients with psoriasis being 
treated with classic systemic therapies and biological agents in participating registries. 
Methods: We pooled data from Psocare (Italy), Dermbio (Denmark), 
BIOBADADERM (Spain), Clalit Health Services (Israel), Australasian Psoriasis 
Registry, Psobest (Germany), and AMC Medical Center Registry (Netherlands).  
Results: A total of 20,232 patients were enrolled in 7 registries, which included 9,668 
who had been treated with biological therapies and 10,564 treated with classic systemic 
therapies. Differences in age, psoriasis severity index (PASI), or types of psoriasis that 
were different to the chronic plaque psoriasis at the baseline between patients receiving 
classic systemic and biological therapies were heterogeneous among national registries. 
Differences between patients receiving classic systemic drugs and biological therapies 
were homogeneous among countries for Body Mass Index (BMI) (mean difference = 
0.42 BMI units; 95% CI: 0.25–0.58), proportion of current smokers (Odds Ratio (OR)= 
0.89, 95% CI: 0.80–0.99), and current alcoholic drinkers (OR = 0.94, 95% CI: 0.87–
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1.01). Despite the heterogeneity observed, in most registries those receiving a biological 
agent were more likely to have psoriatic arthritis or nail psoriasis than those receiving 
classic systemic drugs. No association was documented between PASI at entry and 
treatment selection. 
Conclusions: Among national treatment registries, the baseline characteristics of 
psoriatic patients treated with classic systemic agents versus biological therapies varied 
substantially. Higher BMI and not smoking were associated with a higher likelihood of 
receiving biological therapy. Psoriatic arthritis and nail psoriasis were associated with a 
higher chance of receiving biological therapies in the majority of the registries.  
 
Article 5. Registries as real-world cohort studies that are useful and necessary in 
the pyramid of evidence 
The present article is a brief description of the benefits of psoriasis registries, as well as 
provides tools for dealing with the inherent limitations of these cohort studies. 
Registries are useful to explore the association between drug exposure and many long-
term outcomes that have not been explored in clinical trials. Many exposures cannot be 
randomised and it is from cohort studies that some risk factors for cardiovascular 
diseases, many of the harmful effects of smoking, the effect of radiation, and many 
other medical breakthroughs have been documented. Registry data can provide useful 
results and show a clear position in the pyramid of evidence if we move away from 
survival studies and follow the existing guidelines for analysing and reporting 
observational studies and registry results. 
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Introducción 
 
La psoriasis es una enfermedad de la piel crónica, inmunomediada, que afecta a 
personas de todas las edades y a ambos géneros por igual. Se ha calculado que entre 1 y 
2% de la población sufre psoriasis. De los afectados, aproximadamente 
10% sufre formas graves. Tradicionalmente, las opciones terapéuticas para tratar la 
psoriasis moderada a severa han sido limitadas. Tres de los llamados fármacos "no 
biológicos" han sido las terapias sistémicas más comúnmente utilizadas en todo el 
mundo: acitretino, ciclosporina y metotrexato. Los medicamentos biológicos han sido 
autorizados para su uso en formas moderadas y graves de psoriasis: antagonistas del 
factor de necrosis tumoral (TNF) (infliximab, etanercept y adalimumab) y un 
antagonista de IL-12/23 (ustekinumab). Sin embargo, existen dudas acerca de la 
seguridad a largo plazo, así como incertidumbres sobre efectividad en la práctica clínica 
diaria y con pacientes que tienen características diferentes a los reclutados en ensayos 
clínicos aleatorizados, que necesitan ser respondidas. Desde la aprobación del primer 
anti-TNF para el tratamiento de la psoriasis en placas crónica de moderada a grave, se 
han establecido varios registros a nivel nacional que buscan evaluar la seguridad a largo 
plazo de los medicamentos biológicos. En España se estableció el registro 
BIOBADADERM con este objetivo. 
 
Objetivos 
Uno de los principales objetivos de esta tesis es describir las infecciones que ocurrieron 
en pacientes que recibieron medicamentos biológicos y aquellos que recibieron 
fármacos sistémicos no biológicos en el registro español de terapia sistémica en 
psoriasis, BIOBADADERM; comparar el riesgo de infecciones , riesgo de infecciones 
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graves y riesgo de recurrencia de la infección en cada una de las diferentes terapias 
biológicas y no biológicas con el del metotrexato; y evaluar los cambios en la tasa de 
infección general durante el período de estudio. 
El segundo objetivo principal de esta tesis es describir y comparar la supervivencia de 
diferentes agentes sistémicos biológicos (infliximab, etanercept, adalimumab y 
ustekinumab) y clásicos (ciclosporina, metotrexato, acitretina) en psoriasis, utilizando 
datos del registro BIOBADADERM, verificar el valor del análisis de supervivencia 
para medir la seguridad y describir críticamente los factores que influyen en este tipo de 
análisis en psoriasis. 
El último objetivo de esta tesis es describir y comparar los datos demográficos basales y 
las características clínicas de los pacientes tratados con terapias sistémicas clásicas y 
biológicas en los registros participantes en Psonet, una red internacional de registros de 
psoriasis. 
 
Material y métodos 
 
Para los estudios presentados en esta tesis se utilizaron datos del registro 
BIOBADADERM y de la iniciativa PSONET. 
BIOBADADERM, el registro español de terapia sistémica en psoriasis, es un estudio de 
cohorte prospectivo multicéntrico basado en la práctica clínica con doce departamentos 
de dermatología en toda España que participan desde 2008. 
Psonet es una red internacional de registros nacionales independientes que tiene como 
objetivo documentar el uso "en la vida real" de medicamentos sistémicos para la 
psoriasis en diferentes países y está diseñada para combinar datos de múltiples registros 
internacionales independientes de psoriasis. Los objetivos de Psonet incluyen 
proporcionar estimaciones de la seguridad de estos tratamientos en el uso a largo plazo 
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y describir las diferencias entre los países en el uso de terapias sistémicas biológicas y 
clásicas. 
 
Resultados 
Artículo 1. Infecciones en pacientes con psoriasis moderada a grave tratados con 
medicamentos biológicos en comparación con medicamentos sistémicos clásicos: 
hallazgos del registro BIOBADADERM 
Introducción: la información sobre la seguridad de los fármacos biológicos prescritos a 
pacientes con psoriasis en bases diarias y de larga duración es insuficiente. 
Métodos: utilizamos datos del registro BIOBADADERM (Registro Español de Eventos 
Adversos para Terapia Biológica en Enfermedades Dermatológicas) para generar tasas 
brutas de infección durante el tratamiento con fármacos sistémicos, que incluyen 
medicamentos biológicos (infliximab, etanercept, adalimumab y ustekinumab) y 
medicamentos no biológicos (acitretino, ciclosporina y metotrexato). También 
calculamos las razones de riesgo (RR) ajustadas y no ajustadas (con ajuste del puntaje 
de propensión) de infección, infecciones graves e infecciones recurrentes de terapias 
sistémicas en comparación con el metotrexato, utilizando la regresión de Poisson. 
Resultados: nuestro estudio incluyó registros de 2,153 pacientes (7,867.5 años-persona). 
El RR ajustado de la infección general aumentó significativamente en los grupos 
tratados con adalimumab con metotrexato (RR ajustado = 2,13, intervalo de confianza 
[IC] del 95% = 1,2-3,7), infliximab (RR ajustado = 1,71; IC del 95% = 1,1-2,65 ), 
ciclosporina (RR ajustado = 1.58, IC 95% = 1.17-2.15), ustekinumab con metotrexato 
(RR ajustado = 1.56, IC 95% = 1.08-2.25) y etanercept (RR ajustado = 1.34, IC 95% = 
1.02- 1.76) comparado con metotrexato solo. La ciclosporina tuvo un riesgo 
significativo de infección grave (RR ajustado = 3,12; IC del 95% = 1,1-8,8), seguido de 
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adalimumab combinado con metotrexato (RR ajustado = 3,28, IC del 95% = 0,8-13,5). 
El adalimumab en combinación con metotrexato tuvo el mayor riesgo de recurrencia de 
la infección (RR ajustado = 4.33, IC 95% = 2.27-8.24). 
Conclusión: solo el acitretino tuvo un riesgo ajustado significativamente menor que el 
metotrexato, y el metotrexato puede considerarse una referencia para la seguridad en 
términos de infecciones. 
 Se necesitan más datos sobre la seguridad de combinar drogas biológicas 
y metotrexato en pacientes con psoriasis. Finalmente, nuestro estudio no mostró 
cambios significativos a lo largo del tiempo en la tasa de incidencia de infecciones entre 
pacientes que tomaban metotrexato y pacientes que tomaban otras drogas o 
combinaciones de medicamentos. 
 
Artículo 2. Supervivencia de fármacos sistémicos clásicos y biológicos en psoriasis: 
resultados del registro BIOBADADERM y análisis crítico 
Introducción: pocos estudios han comparado la supervivencia del fármaco en la 
psoriasis vulgar de moderada a grave. 
Objetivos: describir y comparar la supervivencia farmacológica de fármacos 
sistémicos, incluidos agentes biológicos (infliximab, etanercept, adalimumab y 
ustekinumab) y fármacos clásicos (acitretina, ciclosporina y metotrexato) en la psoriasis 
moderada a grave. 
Métodos: se trata de un estudio multicéntrico, prospectivo, de cohortes de pacientes que 
recibieron terapias sistémicas entre 2008 y 2013 en 12 hospitales en España. Se 
recogieron los datos basales y la interrupción de medicamentos. La supervivencia del 
fármaco se presenta usando curvas de supervivencia de Kaplan-Meier. Además, se 
Analysis of survival and infection risk of systemic drugs in the treatment of psoriasis  
| Paula Davila Seijo 
 
 17 
comparan las razones de riesgo ajustadas de eventos adversos graves (EA) con los 
resultados del análisis de supervivencia para EA. 
Resultados: Se incluyeron un total de 1956 pacientes para el análisis (1240 expuestos a 
productos biológicos durante el seguimiento y 1076 a las terapias clásicas). La mediana 
del tiempo de seguimiento fue 3.3 años (0.0-5.1 años). Hubo 2209 interrupciones de 
3640 ciclos de terapia iniciados. El motivo principal de la interrupción fue la falta de 
eficacia (36,4%) y la remisión (27,2%). Los fármacos biológicos mostraron una mayor 
supervivencia que los clásicos y el patrón de resultados de supervivencia para todos los 
resultados (positivos o negativos) fue muy similar. Las razones de riesgo ajustadas de 
EA graves no concuerdan con los resultados del análisis de supervivencia. 
Limitaciones: una limitación es que este es un estudio observacional con posible sesgo 
de selección. 
Conclusión: la supervivencia como una medida indirecta de la seguridad de los 
medicamentos en la psoriasis es inadecuada. 
 
Artículo 3. El análisis de supervivencia de drogas no es un buen método para 
evaluar la seguridad o eficacia de las terapias sistémicas en la psoriasis 
Hay un número creciente de publicaciones que describen la supervivencia de los 
tratamientos sistémicos para la psoriasis moderada a severa. Este concepto se ha 
utilizado en diversas enfermedades crónicas como un indicador de la efectividad general 
de una terapia, dada la asociación de la supervivencia con la eficacia, los efectos 
secundarios y la satisfacción del paciente. Sin embargo, debido a que la supervivencia 
del fármaco está asociada con muchas variables, es difícil de interpretar. Las 
comparaciones entre diferentes estudios o diferentes medicamentos son generalmente 
imposibles, y se generan muchos hallazgos discrepantes. 
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En este artículo, discutimos algunos problemas y limitaciones de los estudios de análisis 
de supervivencia en psoriasis que ilustran por qué los estudios de supervivencia no 
ofrecen una buena forma de evaluar la seguridad o efectividad de los tratamientos de la 
psoriasis y por qué son particularmente inapropiados para comparar tratamientos. En un 
estudio reciente que utilizó los datos de registro de BIOBADADERM, se demostró que 
la supervivencia de fármacos en psoriasis (artículo 2) utilizada como indicador indirecto 
de la seguridad era engañosa. 
Creemos que la mejor manera de medir la seguridad de un fármaco es publicar las tasas 
de eventos adversos en los estudios de cohortes. La efectividad se demuestra mejor a 
través de estudios experimentales u observacionales en los que se especifica la 
efectividad como medida de resultado. El análisis de supervivencia del fármaco, con 
todos sus problemas inherentes, puede ser de interés principalmente para generar 
modelos para evaluar el costo del tratamiento. 
 
Artículo 4. Factores asociados con la recepción de productos biológicos o terapia 
sistémica clásica para la psoriasis moderada a severa: evidencia de los registros de 
PSONET 
Introducción: la red Psonet combina datos de registros internacionales de psoriasis 
para evaluar el uso y la seguridad de las terapias sistémicas para psoriasis. 
Documentamos heterogeneidad en el uso de terapias sistémicas entre países. 
Objetivos: describir y comparar las características de los pacientes tratados con terapias 
sistémicas clásicas y agentes biológicos para la psoriasis en los registros participantes. 
Métodos: Agrupamos datos de Psocare (Italia), Dermbio (Dinamarca), Biobadaderm 
(España), Clalit Health Services (Israel), Australasian Psoriasis Registry, Psobest 
(Alemania) y AMC Medical Center Registry (Países Bajos). 
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Resultados: 20.232 pacientes se inscribieron en 7 registros, incluyendo 9,668 tratados 
con fármacos biológicos y 10,564 con terapias sistémicas clásicas. Las diferencias al 
inicio en edad, PASI o tipos de psoriasis diferentes de la psoriasis en placa crónica entre 
los pacientes que recibieron medicamentos sistémicos clásicos y biológicos fueron 
heterogéneos entre los registros nacionales. Las diferencias entre los pacientes que 
recibieron fármacos sistémicos clásicos y biológicos fueron homogéneos en todos los 
países para el índice de masa corporal (IMC) (diferencia de medias = 0,42 unidades de 
IMC, IC del 95%: 0,25-0,58), proporción de fumadores actuales (OR = 0,89, IC del 
95%: 0,80-0,99) y bebedores actuales (OR = 0.94, 95% CI: 0.87-1.01). A pesar de la 
heterogeneidad, observamos que, en la mayoría de los registros, los pacientes que 
recibían un agente biológico eran más propensos a tener artritis psoriásica o afectación 
ungueal. No se documentó ninguna asociación entre PASI al ingreso y la selección del 
tratamiento. 
Conclusiones: en los registros nacionales, las características iniciales de los pacientes 
con psoriasis tratados con agentes sistémicos versus biológicos varían sustancialmente. 
Un mayor IMC y el no fumar se asociaron con una mayor probabilidad de recibir 
terapia biológica. La artritis psoriásica y la afectación ungueal se asociaron con una 
mayor probabilidad de recibir productos biológicos en la mayoría de los registros. 
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Artículo 5. Los registros como estudios de cohortes del mundo real que son útiles y 
necesarios en la pirámide de evidencia 
Este artículo es una breve descripción de los beneficios de los registros de psoriasis, así 
como las herramientas para hacer frente a las limitaciones inherentes de estos estudios 
de cohortes. 
Los registros son útiles para explorar la asociación entre la exposición al fármaco y 
muchos resultados a largo plazo que no se han explorado en ensayos clínicos. Después 
de todo, muchas exposiciones no se pueden aleatorizar y es a partir de los estudios de 
cohortes que hemos documentado algunos factores de riesgo de enfermedades 
cardiovasculares, muchos de los efectos nocivos del tabaquismo, el efecto de la 
radiación u otros avances médicos. Los datos del registro pueden proporcionar 
resultados útiles y tener una posición clara en la pirámide de evidencia si nos apartamos 
de los estudios de supervivencia y seguimos las pautas ya existentes para analizar los 
estudios observacionales e informar de los resultados del registro. 
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2 Introduction 
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Psoriasis is a chronic immune-mediated skin disease that affects people of all ages and 
both genders equally. It has been calculated that between 1% and 2% of the world 
population suffers from psoriasis1, 2; however, this prevalence varies widely between 
countries (from 0.51% to 11.43%)3. Of these, approximately 10% suffer from severe 
forms. Psoriasis was recognised as a serious non-communicable disease by the World 
Health Organization in 2014 due to its high prevalence, the comorbidities associated 
with this disease, and the low quality of life that patients with psoriasis experience.  
2.1 Pathogenesis  
Psoriasis is considered an immuno-mediated disease whose aetiology is multifactorial. 
Intrinsic factors, such as genetic susceptibility, and extrinsic factors, such as trauma 
(e.g. “Koebner phenomenon”), infections (e.g. streptococcal pharyngitis), or drugs (e.g. 
b-blockers, antimalarial, and so on) play a role in individual susceptibility and the 
initiation and maintenance of the disease4. Genetic studies have identified more than 60 
genetic susceptibility regions that are associated with an increased risk of developing 
psoriasis5. Almost all are genes related to the immune system, both innate and adaptive. 
The best known is HLA-Cw6 that is located on chromosome 6p21.3 (also known as 
psoriasis susceptibility locus 1 [PSORS1] or HLA-C * 06: 02) and is responsible for up 
to 50% of the inheritance of the disease6, 7.  
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Figure 1: Schema summarising the pathogenesis of psoriasis and targeted 
therapies. Figure extracted from G. Girolomoni et al. (2017)8. 
 
The onset of psoriasis lesions can be triggered by an autoimmune skin response initiated 
by factors such as trauma, infections, or autoantigens such as ADAMTSL5 protein from 
cutaneous melanocytes9 or cathelicidin (IL-37)10, which is an antimicrobial peptide 
produced by keratinocytes (Fig. 1). DNA complexes with IL-37 activate the dendritic 
cells present in the dermis, thus releasing inflammatory cytokines such as IL-23 and 
TNF-⍺ through IL-12. IL-23 is a critical cytokine in the inflammatory process in 
psoriasis. It plays a role in the immune response to bacterial and fungal infections; 
however, its deregulation plays a key role in the maintenance of the TH17 (CD4 +) 
lymphocytes, which are the main producers of IL-17A, IL-17F, and IL-22, and whose 
release produces epidermal proliferation and production of inflammatory cytokines such 
as IL-1β, IL-6, and TNF4, 8. 
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2.2 Clinical manifestations and comorbidities 
Inflammation in the skin leads to the lesions seen in the most common type of psoriasis: 
the chronic plaque type. The epidermal hyper proliferation produces the classical white 
scales and skin infiltration by inflammatory cells, and angiogenesis defines the redness 
and elevation of the plaque lesions4.  
The clinical manifestations in psoriasis, however, vary with the different types of 
psoriasis other than the chronic plaque type: 
• Guttate psoriasis: Disseminated small plaque exanthematic form of psoriasis 
seen mostly in children and associated with streptococcal tonsillitis.  
• Nail psoriasis: Psoriatic inflammation of the nail fold and plate that can occur in 
isolation or in combination with other forms of psoriasis.  
• Inverse psoriasis: Psoriasis that affects skin folds and lacks the white scales.  
• Pustular psoriasis: Localised or generalised superficial pustules over 
erythematous skin. It has been recently suggested that, at least, the generalised 
form of pustular psoriasis is a different entity and has been linked to IL-36 
receptor antagonist deficiency or mutations or variants of the caspase 
recruitment domain family, member 14 (CARD14)11, 12. 
 
Psoriasis is associated with multiple diseases. Observational studies have shown an 
increased risk of cardiovascular disease in patients with psoriasis, especially those with 
moderate-to-severe psoriasis13. Psoriasis appears as an independent risk factor for other 
more prevalent risk factors in the population such as smoking or obesity. The theoretical 
explanation is based on the presence of a chronic basal inflammation present in patients 
with psoriasis that encourages the formation of atheromatous plaques in the vessel wall. 
This chronic inflammation induces insulin resistance and metabolic syndrome leading 
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to obesity and non-alcoholic fatty liver, all of which are well-known psoriasis 
comorbidities14.  
 
2.3 Management 
Classically, the therapeutic arsenal to treat moderate-to-severe psoriasis has been 
limited. Three of the so-called “non-biological or classic systemic therapies” (, e.g. 
acitretin, ciclosporine, and methotrexate) are the most commonly used systemic drugs 
worldwide. All of these therapies have non-specific modes of action, an acceptable but 
not great efficacy, and safety concerns when long-term use is required especially renal 
and hepatic toxicity. The first biological drug for the treatment of chronic plaque-type 
psoriasis was approved in Europe in 2005. Biological drugs are those derived from 
biotechnological manipulation, being either monoclonal antibodies or molecules, and 
are synthesised to compete with molecules present in living organisms that aim to 
regulate the cellular and molecular imbalance characteristics of chronic inflammation. 
TNF-⍺ antagonists were the first biological drugs used to treat psoriasis and psoriatic 
arthritis due to the important role of TNF-⍺ in the pathogenesis. Its use produced a 
revolution both in the improvement of disease management and in the knowledge of its 
pathogenesis. Since then, several biological drugs have been authorised for use in 
moderate-to-severe forms of psoriasis: TNF antagonists (e.g. infliximab, etanercept, and 
adalimumab), antagonist of IL-12/23 (e.g. ustekinumab), and recently the IL-17A 
antagonists (e.g. secukinumab and ixekizumab). A new oral non-biological 
phosphodiesterase inhibitor (apremilast) has also been recently approved for the 
treatment of psoriasis. 
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2.4 Safety of biological drugs in psoriasis 
 
Biological agents appear to be an effective, well-tolerated, and safe therapeutic 
alternative to classic drugs such as ciclosporine, methotrexate, or acitretin as shown in 
randomised clinical trials (RCT) in patients with moderate-to-severe psoriasis15. 
However, there are long-term safety concerns, as well as uncertainties about the 
effectiveness in daily clinical practice and with patients who have different 
characteristics than those recruited in RCT16, which need to be answered.  
Clinical trials of these drugs have shown higher rates of serious infections; however, 
this has not been confirmed in all trials because they lack statistical power to 
demonstrate differences with placeboes15, 17-26. 
The safety results of biological drugs for other applications cannot be transferred 
uncritically to psoriasis or dermatological patients27-33. The comorbidity of each of the 
underlying conditions is often different and is expected to alter the safety profile of the 
biological drugs34. 
A recent systematic review and meta-analysis stated that there is still not enough 
evidence about the risk of serious infections with biological drugs in psoriasis patients 
over the long term and in real daily practice, and that further observational studies are 
required35. 
2.5 National registries and long-term safety of biological drugs 
 
Since approval of the first anti-TNF for the treatment of moderate-to-severe chronic 
plaque psoriasis, several registries have been established that seek to assess the long-
term safety of biological drugs36. One of these registries is BIOBADADERM, the 
Spanish registry of systemic therapy in psoriasis, which is a multicentre, prospective 
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cohort study in clinical practice with 12 dermatology departments across Spain who 
have been participating since 2008.  
When dealing with infrequent, yet serious, adverse events of drugs, even a well-
designed prospective national cohort study might fail to show a significant risk because 
of a lack of power to detect it. Combining the results from these registries increases 
their power to detect risks in rare events 37. 
Psonet is an international network of independent national registries that aims to 
document the “real-life” use of systemic drugs for the treatment of psoriasis in different 
countries36, 38, 39 and it is designed to combine data from multiple international 
independent psoriasis registries. The goals of Psonet include providing estimates of the 
safety of these treatments in long-term use and describing differences among countries 
in the use of biological and classic systemic therapies. Differences in the populations 
being treated within the registries have implications for the analysis of data (as these 
factors could act as confounders for the risk estimates), for the generalisability of results 
from individual registries, and for understanding the behaviour of dermatologists in 
different health care systems and countries.  
 
2.6 Drug survival in psoriasis treatment 
 
Survival analysis involves a series of statistical techniques to study the time until the 
occurrence of an event of interest. Initially that event was death, hence the name, and 
death continues to be the endpoint in many studies. However, the application of survival 
analysis has broadened to include the study of time elapsing between many types of 
events. One recent application is the study of drug survival, defined as the time a patient 
continues to take a medication. This concept has been used in different settings (e.g. 
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rheumatoid arthritis and psoriatic arthritis)40-43 as a proxy marker of overall therapy 
effectiveness, as its results are related to efficacy, side effects, and patient satisfaction44. 
There is a growing interest in the description of survival of systemic drugs used for 
psoriasis44-47. 
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3  Objectives 
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Objectives  
 
 
3.1 Risk of infection 
 
One of the main objectives of the present thesis was to describe the infections that 
occurred in patients who received biological drugs and those who received non-
biological systemic drugs from the BIOBADADERM registry.  
This aimed to compare the risk of infections, risk of serious infections, and risk of 
infection recurrences for each of the different biological and non-biological drugs with 
that of methotrexate controlled for confounding factors and to evaluate changes in the 
rate of overall infection during the study period.  
 
3.2 Drug survival 
 
The second main objective of the thesis was to describe and compare drug survival of 
different biological (e.g. infliximab, etanercept, adalimumab, and ustekinumab) and 
classic (e.g. ciclosporine, methotrexate, and acitretin) systemic agents in psoriasis 
treatment, using data from the BIOBADADERM registry, and to check the value of 
survival analysis to measure safety and critically describe the factors that influence this 
type of analysis in psoriasis.  
3.3 Baseline demographics in Psonet network 
 
 The last objective of the present thesis was to describe and compare the baseline 
demographics and clinical characteristics of patients being treated with classic and 
biologic systemic therapies in Psonet participating registries. 
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4 Material and Methods 
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BIOBADADERM registry 
 
For the studies within the present thesis, data extracted from the Spanish Registry of 
Adverse Events of Biological Therapies in Dermatology (BIOBADADERM) were 
used. This registry was initiated in 2008 by the Foundation of the Spanish Academy of 
Dermatology and Venereology at the request of the Spanish Agency for Medicines and 
Health Products, and in collaboration with the Research Unit of the Spanish 
Rheumatology Foundation. 
It is a treatment registry, with its own characteristics, i.e. patients are included as they 
begin the target treatment—in this case, any biological therapy or classic systemic 
drug—and remain there for as long as the exposure lasts. It is not well known whether 
an isolated exposure to biologics has long-term effects or not; therefore, we considered 
that patients were exposed indefinitely, at least for specific adverse events such as 
cancer or slow infections, so that the included patient was followed indefinitely after 
having suspended all biological therapy. Regarding infections, the period of exposure 
from starting the drug to 90 days after the last dose is considered, according to the 
standard used in other registries: “Risk assessment form” from The University of 
Manchester. 
 
The participating centres in BIOBADADERM at the time of these studies are: 
− Hospital Universitario de Gran Canaria Dr Negrín. Las Palmas  
− Hospital Universitari German Trias y Pujol. Badalona, Barcelona  
− Hospital Universitario 12 de Octubre, Madrid 
− Hospital Universitario de la Princesa, Madrid  
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− Hospital General Universitario de Valencia, Valencia  
− Hospital Universitario Reina Sofía, Córdoba  
− Hospital Clínico Universitario Virgen de la Victoria, Málaga  
− Hospital Clinic, Barcelona  
− Hospital Infanta Leonor, Madrid  
− Hospital General Universitario de Alicante, Alicante  
− Fundación Hospital Alcorcón, Alcorcón, Madrid  
− Hospital del Mar. IMAS, Barcelona.  
The number of participant centers increases progressively and currently has sixteen. 
 
Patient selection criteria 
The present thesis included patients who: 
• Began treatment with a biological therapy with the indication of psoriasis in the 
participating centres 
• Authorised the prospective collection of data based on informed consent. 
In case patients had previously received treatment with systemic drugs, this exposure is 
always included in the database to be able to distinguish the patients who are naïve to 
biological drugs from those who are not and to have a record of previous exposures to 
systemic drugs.  
Control group selection 
When a psoriatic patient who begins treatment with biological drugs is included in the 
registry, prospectively, the next psoriatic patient who begins another systemic 
medication and has never received biological drugs is enrolled in the registry. In the 
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case of requiring treatment with biological drugs, these patients of the control group 
become part of the “exposed” cohort. 
 
Variables of interest 
The variables of interest include adverse events or any event that requires suspension or 
changes of treatment or unscheduled medical attention, including changes in the disease 
(worsening or changes in the type of psoriasis). 
The responsible physician has to record the adverse events in two ways: as a text field 
in which the diagnosis is written and by selecting a term from the Medical Dictionary 
for Drug Regulatory Activities nomenclature. 
 
The following information is collected from all patients who have presented an adverse 
event: 
• Date of occurrence of the adverse event 
• Concomitant treatments that the patient was receiving at the time of the 
appearance of the adverse effect 
• Severity of the event based on the legal definition of a serious adverse event 
(Royal Decree 1344/2007 on Pharmacovigilance, EU Directive 2001-83): 
- Produce death 
- Endanger life (real, not hypothetical) 
- Precise hospital admission or prolonged 
- Produce a persistent or important disability 
- Produce congenital malformations 
• Outcome 
• Causality 
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• Data specific in case of infections, including if there was bacteraemia. 
 
Other variables 
The following data is collected systematically: 
• Identification data of the centre 
• From the patients: 
- Sex 
- Birthdate 
- Diagnosis, and date thereof 
- Comorbidity and dates of diagnosis 
• Treatment data: 
- Name of the drug and:  
▪ Start and end dates 
▪ Severity of the disease at the beginning of the treatment 
▪ Cause of interruption 
▪ Concomitant treatments. 
 
Quality control 
The inclusion of patients, treatment modifications, and adverse events are 
communicated at any time. In addition, once a year, or every six months in the case of 
newly approved drugs, the following controls will be undertaken to validate the data: 
• Online monitoring by a person with experience in pharmacovigilance. This is 
done daily to detect any abnormalities in the entered data. 
• On-site monitoring: The study monitor visits each centre annually and verifies 
that the collected data correspond to those that appear in the patient’s history. 
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The same numbers of patients treated with classic systemic and biological 
therapies, chosen at random, are monitored to verify that adverse events are 
collected in the same way in both groups. 
• Phone calls to patients. Trained telephonists will ask about the vital status and 
about possible hospital admissions during the previous year. 
 
The online platform contains filters that limit the entry of unreliable data (range checks 
and logical consistency). 
An annual report is produced and sent to the Spanish Agency of Medicines and Health 
Products (AEMPS). Likewise, the Spanish Pharmacovigilance System has permanent 
access to aggregate information. 
 
The registry is funded by the Foundation of the Spanish Academy of Dermatology and 
Venereology and by AEMPS and unrestricted grants from pharmaceutical companies 
that do not have access to the data or the papers before publication. 
 
The BIOBADADERM registry, including protocol and materials, has been approved by 
AEMPS and the Ethics Committee of the Hospital 12 de Octubre in Madrid (216/07). 
 
PSONET network  
One of the studies of the present thesis was performed with data from the Psonet 
network. Psonet is an international network of national registries with the objective of 
monitoring the long-term efficacy and safety of systemic drugs in psoriasis treatment36, 
39. 
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Psonet was started in 2005, initially with nine participating national registries, with 
funding from the Italian Agency for Medicines and coordinated from the Study GISED 
Center (Bergamo, Italy). The Psonet study was approved by the ethics committee of 
Ospedali Riuniti di Bergamo (Italy). 
The aim of the Psonet network is to achieve a critical mass of data via the development 
of a common methodological platform that allows collaborative analyses, and enables 
the conduct of investigations that would not be feasible in a single country registry: 
  
• Investigation of the clinical effectiveness of systemic treatments for psoriasis, in 
a population context 
• Identification of prognostic factors that can help in predicting the response to 
systemic treatments  
• Monitoring of adverse effects of systemic treatments, with particular attention to 
long-term and rare adverse events, including infections, lymphomas, and other 
cancers.  
The International Coordinating Committee includes representatives of national 
registries (see Table 1). The Coordinating Committee is responsible for the overall 
monitoring of the project, including the definition of working groups on specific 
issues, the definition of data management and analysis, and the approval of reports 
and published papers, privacy, and ethical issues.  
 
 
 
 
 
Analysis of survival and infection risk of systemic drugs in the treatment of psoriasis  
| Paula Davila Seijo 
 
 38 
 
 
 
 
Table 1: Characteristics of national registries participating in Psonet, extracted from 
Ormerod et al.39 
 
 
 
 
 
 
 
 
 
Different aspects of sampling the population covered by registries 
Country Number of centres 
participating in 
registry 
Population of 
country 
millions 
Estimate of  the 
proportion of 
population sampled 
by registry 
Estimated  
Percent of  all 
psoriatic patients 
receiving biologics 
Great Britain 62 66 50% 0.20% 
Spain 13 46 <10% U 
Netherlands 1 16 0.5% U 
Israel 3500 7.7 100% 1.4% 
Italy 164 70 about 80% less than 1% 
Denmark 5 Hospital, 10 
private 
6 >90% 0.20% 
Sweden 50 9 80% 1.6% 
Germany 530  hospital and 
private 
81 10% 0.25% 
Australia 10 22 0.5% U 
France 40 62 U U 
U=Unknown Y=Yes N=No From Ormerod et al, 2012, Dermatology 
accepted 
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5 Chapter 5  
 
 
5.1 Article 1. infections in moderate-to-severe psoriasis 
patients treated with biological drugs compared to 
classic systemic drugs: findings from the 
BIOBADADERM registry 
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Infections in Moderate to Severe Psoriasis
Patients Treated with Biological Drugs
Compared to Classic Systemic Drugs:
Findings from the BIOBADADERM Registry
Paula Da´vila-Seijo1,15, Esteban Dauden2, M.A. Descalzo1, Gregorio Carretero3,
Jose´-Manuel Carrascosa4, Francisco Vanaclocha5, Francisco-Jose´ Go´mez-Garcı´a6,
Pablo De la Cueva-Dobao7, Enrique Herrera-Ceballos8, Isabel Belincho´n9,
Jose´-Luis Lo´pez-Estebaranz10, Merce Alsina11, Jose´-Luis Sa´nchez-Carazo12, Marta Ferra´n13,
Rosa Torrado3, Carlos Ferrandiz4, Raquel Rivera5, Mar Llamas2, Rafael Jime´nez-Puya6 and
Ignacio Garcı´a-Doval1,14 and the BIOBADADERM Study Group
Information regarding the safety of biological drugs prescribed to psoriasis patients on daily and long-term
bases is insufficient. We used data from the BIOBADADERM registry (Spanish Registry of Adverse Events for
Biological Therapy in Dermatological Diseases) to generate crude rates of infection during therapy with
systemic drugs, including biological drugs (infliximab, etanercept, adalimumab, and ustekinumab) and
nonbiological drugs (acitretin, cyclosporine, and methotrexate). We also calculated unadjusted and adjusted
risk ratios (RRs) (with propensity score adjustment) of infection, serious infections, and recurrent infections of
systemic therapies compared with methotrexate, using Poisson regression. Our study included records of 2,153
patients (7,867.5 person-years). The adjusted RR of overall infection was significantly increased in the groups
treated with adalimumab with methotrexate (adjusted RR ¼ 2.13, 95% confidence interval [CI] ¼ 1.2e3.7),
infliximab (adjusted RR ¼ 1.71, 95% CI ¼ 1.1e2.65), cyclosporine (adjusted RR ¼ 1.58, 95% CI ¼ 1.17e2.15),
ustekinumab with methotrexate (adjusted RR ¼ 1.56, 95% CI ¼ 1.08e2.25), and etanercept (adjusted RR ¼ 1.34,
95% CI: 1.02e1.76) compared with methotrexate alone. Cyclosporine had a significant risk of serious infection
(adjusted RR ¼ 3.12, 95% CI ¼ 1.1e8.8), followed by adalimumab combined with methotrexate (adjusted
RR ¼ 3.28, 95% CI ¼ 0.8e13.5). Adalimumab in combination with methotrexate had the highest risk of infection
recurrence (adjusted RR ¼ 4.33, 95% CI ¼ 2.27e8.24).
Journal of Investigative Dermatology (2017) 137, 313e321; doi:10.1016/j.jid.2016.08.034
INTRODUCTION
Psoriasis is a chronic skin disease that affects between 0.91%
and 8.5% of the population (Ferrandiz et al., 2014; Parisi
et al., 2013) across the world. Of those affected, approxi-
mately 10% suffer from severe forms of psoriasis. Tradition-
ally, therapeutic options for treating moderate to severe
psoriasis have been limited. Three of the so-called “nonbi-
ological systemic therapies” were the most commonly used
systemic drugs worldwide: acitretin, cyclosporine,
and methotrexate. Biological drugs have been authorized
for use in moderate and severe forms of psoriasis: tumor
necrosis factor (TNF) antagonists (infliximab, etanercept,
and adalimumab) and one IL-12/23 antagonist
(ustekinumab).
Clinical trials of these drugs have shown high rates
of serious infections in rheumatoid arthritis, but these have
not been confirmed in all trials because of the lack of
statistical power to demonstrate differences from placebo
(Gordon et al., 2012; Reich et al., 2012; Salliot et al.,
2007; Salmon-Ceron et al., 2011; Schmitt et al., 2014;
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Soderlin et al., 2005; Suwannalai et al., 2009; Trautmann,
2012; Trotta and Valentini, 2005; Wood et al., 2003).
Safety claims of biological drugs for other indications
cannot be extrapolated uncritically to psoriasis or dermato-
logical patients (Andersen and Jess, 2014; Atzeni et al., 2012;
Galloway et al., 2011; Garcia-Doval et al., 2016; Sakai et al.,
2012; van Dartel et al., 2013). Comorbidities of each of the
underlying conditions often vary and can be expected to alter
the safety profile of biological drugs (Wakkee et al., 2011).
A recent systematic review and meta-analysis stated that
there was still not enough evidence about the risk of serious
infections from biological drugs in psoriasis patients in
long-term and daily use and that further observational studies
were needed (Yiu et al., 2016).
OBJECTIVES
Our objectives were as follows: (i) to describe the infections
that occurred in patients who received biological drugs and
those who received nonbiological systemic drugs in the
Spanish Registry of Adverse Events for Biological Therapy in
Dermatological Diseases (BIOBADADERM) registry and (ii)
to compare the risk of infections, risk of serious infections,
and risk of infection recurrence for each of the different
biological and nonbiological drugs with those for metho-
trexate and to evaluate changes in the rate of overall infection
during the study period.
RESULTS
At the end of the follow-up period, 2,153 patients were
included for analysis. Of them, 1,074 were exposed to
biologics and 1,079 to nonbiological therapies (some patients
were exposed to both during follow-up), with 7,867.5 person-
years at the end of the follow-up period (see Supplementary
Table S1 online). Only 0.3% of patients declined to
participate. Losses to follow-up numbered 257 (11.9%).
Tables 1 and 2 show the patients’ baseline characteristics
and their drug regimens. Overall, the patient group receiving
biologics had a higher proportion of men and higher preva-
lence of the plaque type of psoriasis and psoriatic arthritis.
The Psoriasis Area Severity Index (PASI) score when starting
therapy, duration of disease at the beginning of treatment,
and the number of previous treatments were also higher in
patients ever receiving biologics.
Risk of overall infections
Infliximab and etanercept in monotherapy showed a signifi-
cant higher risk of overall infection compared with metho-
trexate in the adjusted analysis (Table 3, and see
Supplementary Figure S1 and Supplementary Table S2
online). Among the nonbiological therapies, acitretin
showed the lowest infection risk compared with metho-
trexate (crude risk ratio [RR] ¼ 0.6, 95% confidence interval
[CI] ¼ 0.42e0.86); after multivariable and propensity score
adjustments, this decrease in risk was still significant
(adjusted RR ¼ 0.6, 95% CI ¼ 0.44e0.83). Cyclosporine
showed a 58% higher risk of overall infection than metho-
trexate (adjusted RR ¼ 1.58, 95% CI ¼ 1.17e2.15).
Risk of serious infections
The number of serious infections (Table 4) was low among all
the treatments, with the highest rate in the combined
adalimumab and methotrexate group (adjusted incidence
rate ¼ 23.3, 95% CI ¼ 12.9e42), followed by the cyclo-
sporine group (adjusted incidence rate ¼ 20, 95% CI ¼
8.3e47.9) and the infliximab group (adjusted incidence
rate ¼ 18.9, 95% CI ¼ 7.9e45.5). Because of the small
number of serious infections, it was not possible to obtain
significant RRs compared with methotrexate and the CIs were
wide, especially after adjustment. The combinations of
infliximab and adalimumab with methotrexate had the
highest risk of serious infections compared with methotrexate
alone, although they did not reach significance. Cyclosporine
had a significant higher risk of serious infections than meth-
otrexate in both crude and adjusted analysis (adjusted
RR ¼ 3.12, 95% CI ¼ 1.11e8.77).
Risk of recurrent infections
The crude rate (per 1,000 person-years) of recurrent
infections varied among the therapy groups, from the highest
rate of 80.4 (95% CI ¼ 58.5e110.4) in the combined group
of adalimumab and methotrexate to the lowest rate of 13.3
(95% CI ¼ 6.3e27.9) in the acitretin group. In terms of risk of
recurrent infections (Table 5), the combined adalimumab and
methotrexate group had the higher risk (adjusted RR ¼ 4.33,
95% CI ¼ 2.27e8.24), followed by infliximab (adjusted
RR ¼ 1.98, 95% CI ¼ 1e3.94). Acitretin had a significantly
lower risk of recurrent infections compared with metho-
trexate (adjusted RR ¼ 0.45, 95% CI ¼ 0.23e0.87).
Changes in the rate of infections over the length of the study
Our study found no significant changes over time (see
Supplementary Figure S2 online) in the incident rate (per
1,000 person-years) of infections compared with the incident
rate in patients taking methotrexate, except with ustekinu-
mab, which showed a significant tendency toward
decreasing the rate of overall infections over time.
DISCUSSION
To our knowledge, this is the first multicenter, longitudinal,
disease-based analysis of risk of overall infections, serious
infections, and infection recurrence amongmoderate to severe
psoriasis patients taking both classic and biological systemic
drugs. We found a slight, significant adjusted increase in the
risk of overall infection between the TNF-antagonist drugs and
methotrexate. Acitretin had a 40% lower raw risk of infection
than methotrexate, and this reduction remained significant in
the adjusted analysis.
The rates of serious infections we found are comparable with
those recently reported in the Psoriasis LongitudinalAssessment
and Registry study (Kalb et al., 2015), a large multicontinental,
prospective psoriasis study, which includes patients frommany
countries, although patients from North America are over-
represented. Similar to the results of our study, the Psoriasis
Longitudinal Assessment and Registry study found that inflix-
imab was the drug with the highest rate of serious infections
(24.9 per 1,000 person-years). Adalimumab was also the drug
with the second-highest rate, but our finding was not as high as
their reported rate of 19.7 per 1,000 person-years. Our study
found that etanercept had the smallest unadjusted rate of all
drugs (1.6 per 1,000 person-years), whereas the Psoriasis Lon-
gitudinal Assessment and Registry study found a rate of 14.7 per
1,000 persons-years for etanercept.
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The RR between different drugs compared with a reference
drug was not calculated in the Psoriasis Longitudinal
Assessment and Registry study, the rate of cyclosporine and
acitretin is reported together, and those patients who were
treated with a combination of one biological drug and
methotrexate are not analyzed specifically.
Risk of serious infection in other diseases
Not much data are available about infection risk
and serious infection risk in psoriasis patients under
systemic therapy (Yiu et al., 2016). Most post-
commercialization long-term studies and registries involve
rheumatoid arthritis patients treated with TNF
Table 2. Baseline characteristics of patients who received combined therapy of a biological drug and methotrexate1
Characteristic
Etanercept Infliximab Adalimumab Ustekinumab
In Combination with Methotrexate
Number of patients, n (%) 88 (100) 74 (100) 130 (100) 84 (100)
Women, n (%) 42 (47.7) 22 (29.7) 54 (41.5) 28 (33.3)
Age, years (SD) 50.5 (13.7) 49.9 (11.5) 48.2 (10.4) 49.6 (11.7)
Duration of disease at start of treatment,
median years (p25ep75)
17.4 (10.9e2) 18.7 (10.7e30) 18.1 (10.5e27.3) 18.1 (11.1e26.3)
PASI, median (p25ep75) 8.4 (5.4e13.2) 15 (7.2e22.5) 11.4 (5.1e16) 12 (8e18)
Diagnosis at registration in cohort, n (% of total)
Plaque psoriasis 84 (95.5) 66 (89.2) 121 (93.1) 81 (96.4)
Other forms 7 (8) 9 (12.2) 8 (6.2) 5 (6)
Psoriatic arthritis2 25 (28.4) 16 (21.6) 37 (28.5) 24 (28.6)
Comorbidities, n (% of total patients)
Ischemic cardiopathy 0 (0) 1 (1.4) 3 (2.3) 2 (2.4)
Arterial hypertension 14 (15.9) 19 (25.7) 36 (27.7) 23 (27.4)
Diabetes 5 (5.7) 13 (17.6) 14 (10.8) 9 (10.7)
Hypercholesterolemia 20 (22.7) 22 (29.7) 33 (25.4) 27 (32.1)
Cancer in the past 5 years3 2 (2.3) 1 (1.4) 2 (1.5) 2 (2.4)
Chronic hepatopathy 1 (1.1) 3 (4.1) 1 (0.8) 2 (2.4)
Chronic renal failure 0 (0) 2 (2.7) 0 (0) 0 (0)
COPD 1 (1.1) 0 (0) 1 (0.8) 2 (2.4)
Hepatitis B 2 (2.3) 5 (6.8) 3 (2.3) 4 (4.8)
Hepatitis C 1 (1.1) 2 (2.7) 0 (0) 0 (0)
HIV 0 (0) 0 (0) 2 (1.5) 1 (1.2)
Abbreviations: COPD, chronic obstructive pulmonary disease; p25ep75, 25th percentile 25 to 75th percentile; PASI, Psoriasis Area Severity Index; SD,
standard deviation.
1Columns list the drugs taken with methotrexate. Total number of patients was 2,153.
2Other forms of psoriasis: erythrodermic psoriasis, generalized pustular psoriasis, palmoplantar pustulosis, annular pustular psoriasis, and acrodermatitis
continua of Hallopeau.
3Excluding nonmelanoma skin cancer.
Table 3. Infection crude rates (per 1,000 person-years) and crude and adjusted incidence RR of infection compared
with methotrexate1
Person-time Failures Rate (95% CI) Crude RR (95% CI) Adjusted RR (95% CI)
Etanercept 1,228.6 183 148.9 (128.9e172.2) 1.23 (0.94e1.62) 1.34 (1.02e1.76)2,5
Infliximab 264.2 56 211.9 (163.1e275.4) 1.63 (1.09e2.44)5 1.71 (1.10e2.65)5
Adalimumab 1,329.7 195 146.6 (127.4e168.7) 1.22 (0.89e1.66) 1.27 (0.92e1.75)3
Ustekinumab 1,194.0 138 115.6 (97.8e136.6) 0.91 (0.62e1.34) 0.93 (0.64e1.36)4
Methotrexate 1,149.4 130 113.1 (95.2e134.3) 1.00 1.00
Cyclosporine 250.6 43 171.6 (127.3e231.4) 1.57 (1.17e2.12)6 1.58 (1.17e2.15)6
Acitretin 526.8 34 64.5 (46.1e90.3) 0.6 (0.42e0.86)6 0.6 (0.44e0.83)6
Etanercept combined with methotrexate 284.7 31 105.7 (73.0e153.1) 1 (0.50e1.99) 1.02 (0.52e1.99)2
Infliximab combined with methotrexate 225.6 25 104 (68.5e158.0) 1.12 (0.59e2.11) 1.23 (0.68e2.23)
Adalimumab combined with methotrexate 472.9 91 195.6 (157.7e242.6) 2.04 (1.28e3.26)6 2.13 (1.23e3.67)3,6
Ustekinumab combined with methotrexate 340.2 56 173.2 (132.0e227.3) 1.39 (0.96e2.02) 1.56 (1.08e2.25)4,5
Abbreviations: CI, confidence interval; RR, risk ratio.
1Adjusted for age, sex, and propensity score of each drug compared with methotrexate.
2Additional adjustment for baseline Psoriasis Area Severity Index and psoriasis arthritis.
3Additional adjustment for disease duration.
4Additional adjustment for diabetes and history of tuberculosis.
5P < 0.05.
6P < 0.01.
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antagonists compared with methotrexate (Garcia-Doval
et al., 2016).
Compared with other systemic diseases in which biologics
are also used, our study found that psoriasis patients treated
with TNF-antagonist drugs (etanercept, infliximab, and adali-
mumab) had a lower rate of serious infections compared with
rheumatoid arthritis patients treated with TNF-antagonist
drugs. Data from the British Society for Rheumatology
Biologics Register, a database for a large national prospective
study that analyzed data from 15,395 patients (11,798 in the
TNF antagonist cohort and 3,598 in the nonbiologics cohort)
with a median follow-up duration of 3.9 years, showed an
unadjusted incidence rate of 38 per 1,000 person-years (95%
CI¼35e42) in the group treatedwith etanercept, an incidence
rate of 46 per 1,000 person-years (95% CI ¼ 42e50) in the
group treated with infliximab, and an incidence rate of 43 per
1,000 person-years (95% CI ¼ 39e47) in the group treated
with adalimumab. Similar results were found in other pro-
spective cohort studies (Atzeni et al., 2012; Sakai et al., 2012;
van Dartel et al., 2013). This reinforces the idea that psoriasis
and rheumatoid arthritis cannot be compared, because of their
different underlying immunologic alterations and the resulting
treatment-specific comorbidities.
Infection recurrence
The raw rate of recurrent infections in the same patient
appeared to be higher among patients treated with biologics
compared with those treated with methotrexate, and it was
lower among patients who were treated with cyclosporine or
acitretin. This can be due, especially when time at risk is
Table 4. Serious and deadly infection crude rates (per 1,000 person-years) and crude and adjusted1 incidence RR
of serious and deadly infections compared with methotrexate
Person-Time Failures Rate (95% CI) Crude RR (95% CI) Adjusted RR (95% CI)
Etanercept 1,228.6 2 1.6 (0.4e6.5) 0.17 (0.03e0.91)5 0.24 (0.04e1.29)2
Infliximab 264.2 5 18.9 (7.9e45.5) 1.27 (0.49e3.31) 2.52 (0.83e7.69)
Adalimumab 1,329.7 13 9.8 (5.7e16.8) 0.92 (0.46e1.84) 1.29 (0.72e2.32)3
Ustekinumab 1,194.0 7 5.9 (2.8e12.3) 0.59 (0.12e2.87) 0.75 (0.18e3.13)4
Methotrexate 1,149.4 11 9.6 (5.3e17.3) 1 1
Cyclosporine 250.6 5 20 (8.3e47.9) 2.21 (1.02e4.81)5 3.12 (1.11e8.77)5
Acitretin 526.8 4 7.6 (2.8e20.2) 0.8 (0.33e1.91) 0.82 (0.35e1.92)
Etanercept combined with methotrexate 284.7 2 7 (1.8e28.1) 0.37 (0.11e1.3) 0.56 (0.15e2.1)
Infliximab combined with methotrexate 225.6 2 8.9 (2.2e35.4) 2.11 (0.64e6.95) 3.4 (0.76e15.21)
Adalimumab combined with methotrexate 472.9 11 23.3 (12.9e42) 2.5 (0.7e8.89) 3.28 (0.8e13.46)3
Ustekinumab combined with methotrexate 340.2 3 8.8 (2.8e27.3) 1.05 (0.24e4.52) 1.63 (0.43e6.13)4
Abbreviations: CI, confidence interval; RR, risk ratio.
1Adjusted for age, sex, and propensity score of each drug compared with methotrexate.
2Additional adjustment for baseline Psoriasis Area Severity Index and psoriasis arthritis.
3Additional adjustment for disease duration.
4Additional adjustment for diabetes and history of tuberculosis.
5P < 0.05.
Table 5. Recurrent infections crude rates (per 1,000 person-years) and crude and adjusted1 incidence risk ratio
of recurrent infections compared to methotrexate
Person-Time Failures Rate (95% CI) Crude RR (95% CI) Adjusted RR (95% CI)
Etanercept 1,228.6 70 57 (45.1e72) 1.18 (0.82e1.71) 1.4 (0.93e2.1)2
Infliximab 264.2 21 79.5 (51.8e121.9) 1.81 (0.86e3.82) 1.98 (1e3.94)
Adalimumab 1,329.7 66 49.6 (39e63.2) 1.03 (0.7e1.53) 1.06 (0.67e1.67)3
Ustekinumab 1,194.0 45 37.7 (28.1e50.5) 0.77 (0.36e1.61) 0.8 (0.37e1.75)4
Methotrexate 1,149.4 39 33.9 (24.8e46.4) 1 1
Cyclosporine 250.6 5 20 (8.3e47.9) 0.78 (0.43e1.43) 0.63 (0.3e1.31)
Acitretin 526.8 7 13.3 (6.3e27.9) 0.43 (0.23e0.8)6 0.45 (0.23e0.87)5
Etanercept combined with methotrexate 284.7 8 28.1 (14.1e56.2) 0.86 (0.37e2) 0.75 (0.37e1.49)2
Infliximab combined with methotrexate 225.6 3 13.3 (4.3e41.2) 0.61 (0.17e2.21) 0.66 (0.18e2.44)
Adalimumab combined with methotrexate 472.9 38 80.4 (58.5e110.4) 3.83 (2.47e5.95)6 4.33 (2.27e8.24)3,6
Ustekinumab combined with methotrexate 340.2 25 73.5 (49.7e108.8) 1.95 (0.49e7.71) 2.18 (0.63e7.48)4
Abbreviations: CI, confidence interval; RR, risk ratio.
1Adjusted for age, sex, and propensity score of each drug compared with methotrexate.
2Additional adjustment for baseline psoriasis area severity index (PASI) and psoriasis arthritis.
3Additional adjustment for disease duration.
4Additional adjustment for diabetes and history of tuberculosis.
5P < 0.05.
6P < 0.01.
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evaluated, to the fact that methotrexate and all classic drugs
for psoriasis are usually administered in cycles, and treat-
ment ceases when patients improve because of concerns
regarding potential organ damage from long-term use. In
particular, the liver is at risk from methotrexate treatment,
and the kidneys are at risk from cyclosporine treatment. If a
drug is not used continuously, which is the present standard
of psoriasis therapy with biological drugs, a patient may not
be at prolonged risk of recurrent infections. However,
infliximab showed the highest rate of recurrent infections of
all biologics, despite having the smallest time at risk. Inflix-
imab also had the highest relative risk of recurrent infection
compared with methotrexate of any biologics in both the
unadjusted and adjusted analysis. Another factor that could
bias this analysis is a depletion of susceptible bias: patients
with previous infection could be offered alternative
therapies.
Combination therapy
Our study also analyzed the risk of infection among patients
undergoing combination therapy of a biological drug and
methotrexate. This combination is not uncommon in clinical
practice, especially for optimizing efficacy in patients who
receive treatment with biologics and who do not reach the
desired level of improvement. To date, there are not enough
data available about the risk of infection in psoriasis patients
treated with a combination of one of the biologics and meth-
otrexate (Armstrong et al., 2015; Yiu et al., 2016). On the basis
of mostly long-term data from psoriatic arthritis and rheuma-
toid arthritis (Breedveld et al., 2006; Greenberg et al., 2010),
the combination of adalimumabwith methotrexate appears as
a suggested option in the latest guidelines (Cather and
Crowley, 2014; Nast et al., 2015). A recent report from a
500,000eperson-year study in Israel found that the combina-
tion of biologics with methotrexate was significantly associ-
ated with an increased incidence of herpes zoster (Shalom
et al., 2015).
Our study shows a tendency toward increasing rate and
relative risk of serious infections for all biologics in combi-
nation with methotrexate, compared with the same biologic
in monotherapy, despite having a much smaller person/time-
at-risk cohort in the combination therapy groups. If this
finding is confirmed in other studies, it could have important
consequences for clinical practice.
Changes in infection risk over time
The last objective of our study was to evaluate the evolution
in time of the rate of infection among patients taking different
drugs. We found that the incidence rate of overall infection in
all the systemic treatment groups did not change significantly
over time in any of the treatments. This contrasts with the
reported risk of infections among patients with rheumatoid
arthritis treated with TNF-antagonist drugs (etanercept,
infliximab, and adalimumab), which appeared to be higher
during the first year of treatment and then became nearly
constant (Sakai et al., 2012; van Dartel et al., 2013). In our
study, only ustekinumab showed a significant trend for a
reduction in the overall infection risk over time, and doubt
regarding a constant basal rate arose only in the last period of
follow-up; this change may be due to the lower sample size
during this period.
Limitations
Our study has some limitations. First, it is observational and
may suffer from selection bias in the treatments for each
patient. Drug allocation was not randomized but was a
reflection of common use, leading to groups that were not
comparably similar at baseline and possibly confounding by
indication. To decrease this potential bias, we adjusted for
the propensity score of each drug in the multivariable anal-
ysis. In our study, patients who received biologics at any time
skewed toward a higher proportion of women and a higher
prevalence of plaque-type psoriasis and psoriatic arthritis, a
higher PASI score at the start of therapy, longer duration of
disease at commencement of treatment, and number of
previous treatments. With the propensity score technique,
we could remove the indication bias from the non-
randomization of patients from the baseline covariates: pa-
tients in the comparison groups (treatment of interest group
and control) who have similar propensity scores will have
nearly the same distribution in the baseline covariates. We
did this adjustment as an extra step to control for potential
confounders originating from the differences in the baseline
covariates distribution; these confounders can emerge from
subjectively favoring one treatment over another because the
patients have some specific baseline characteristic. Use of
this methodology is an important strength of our study
compared with previous studies of infection in psoriasis.
There can be, however, residual confounding due to non-
collected variables, such as inflammatory bowel disease.
Information bias in reporting of adverse events by physi-
cians or patients is also possible. To avoid it, we used stan-
dardized definitions of adverse events that should be
reported, frequent training of data collectors, and data
monitoring. We also established a threshold for including
adverse events in the registry (those that led to changes in
therapy or caused an unexpected visit to the doctor).
The prescribed doses were not collected. This could mean
some error in the measurement of exposure, possibly influ-
encing the results.
Strengths
One of the strengths of our study is that the studied popula-
tion was highly representative of psoriasis patients in clinical
practice. Another is the quality of the data in the
BIOBADADERM registry. Our study analyzed data from a
large number of patients from different hospitals in Spain and
included patients who were not represented in clinical trials.
In addition, and this is one of the study’s strengths relative to
other published studies of infection in psoriasis, we included
data on classic drugs and took into account simultaneous use
of biologics and classic drugs. We also differentiated be-
tween patients who were treated with two immunosuppres-
sive treatments in combination therapy (biological drug and
methotrexate) from those treated with only one drug. This is
important because the addition of methotrexate could
potentially increase the risk of infection.
CONCLUSIONS
In terms of infection prevention, only acitretin had a signifi-
cant lower adjusted risk than methotrexate, and methotrexate
can be considered a reference for safety in terms of
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infections. The adjusted RR of overall infections was signifi-
cantly increased in the groups treated with adalimumab with
methotrexate, infliximab, cyclosporine, and ustekinumab
combined with methotrexate. Cyclosporine was the only
drug that showed a significant increased risk of serious in-
fections compared with methotrexate (adjusted RR ¼ 3.12,
95% CI ¼ 1.1e8.8). Adalimumab in combination with
methotrexate had the highest risk of infection recurrence
(adjusted RR ¼ 4.33, 95% CI ¼ 2.27e8.24). More data are
needed regarding the safety of combining biological drugs
and methotrexate in psoriasis patients.
Finally, our study showed no significant change over time
in the incidence rate of infections between patients taking
methotrexate and patients taking other drugs or drug
combinations. Unlike the reported risk in rheumatoid
arthritis, infection risk in psoriasis patients under biologics
therapy does not seem to be higher during the first year of
use.
MATERIALS AND METHODS
This study was based on data from BIOBADADERM, a multicenter,
prospective cohort study in clinical practice. BIOBADADERM has
been previously described (Carrascosa et al., 2013; Garcia-Doval
et al., 2012; Sanchez-Moya et al., 2013). All patients gave written
informed consent to participate. The study was approved by an
ethics committee and performed in compliance with the Declaration
of Helsinki and local regulations.
Twelve dermatology departments across Spain participated.
BIOBADADERM began in 2008. We included all prospective data
from January 2008 through November 2015. Biologics have been
commercially available in Spain since 2005. The National Health
System covers the cost of all study drugs in most circumstances.
All patients with moderate to severe psoriasis who started a
therapy with biologics (incident users for the specific drug) in
participating centers were included in BIOBADADERM. As a com-
parison group, a systematic sample of psoriasis patients receiving
nonbiological systemic therapy for the first time was collected. These
were patients who started a course of methotrexate, cyclosporine, or
acitretin after January 2008. Once patients in this group received a
biological drug, they were moved to the biologics group. The
treating physician determined the treatment dose.
The only exclusion criterion was the patient’s refusal to partici-
pate. Patient follow-up continued as long as possible. All partici-
pants were monitored at least once a year, but several visits during a
year were commonly made as part of usual care. Any adverse events
were included in the database if they were serious or led to a change
in therapy or to an unplanned health care demand. To ensure high
quality data, BIOBADADERM monitors the clinical records from
each center periodically.
The use of the BIOBADADERM registry for this study, including
protocol and materials, has been approved by the Spanish Agency of
Medicines and Health Products (AEMPS) and Ethics Committee of
the Hospital 12 de Octubre in Madrid (216/07).
Statistical analysis
Data were analyzed using Stata 14.1 (StataCorp, College
Station, TX). Demographic and descriptive data were presented as
proportions in discrete quantitative variables and as mean and
standard deviation in continuous quantitative data. To handle
missing data, we use a complete-case analysis, because we assume
that the missing data pattern was Missing at Random.
Serious infections are those that resulted in death, were life-
threatening, required prolonged hospitalization, or caused persis-
tent disability.
We considered an infection as recurrent if the patient had
already experienced another infection during therapy with the
same drug.
We used methotrexate as the comparator with all the drugs
(included classics and biologics) because it represents a standard of
therapy and the largest group among classic therapies. We pro-
duced crude rates of infection and crude risk ratios of infection,
serious infections, and recurrent infections compared with
methotrexate.
To reduce the bias from noncontrol of treatment assignment in the
nonrandomized cases, we calculated the propensity score of indi-
cation for each drug compared with methotrexate. In our study, we
used all the covariates recorded to create a propensity score for each
drug and then included it in the multivariable analysis, as an extra
step to minimize potential bias in our cohort study as much as
possible.
Adjusted RRs were calculated using Poisson regression with
robust standard errors to take into account clustering of outcomes by
patient. We used a Poisson mixed-model regression considering the
center as a random effect to take into account within-center clus-
tering of patients. Initially, we included all the covariates that
appeared to be significantly associated with the outcome in the
analysis of each drug, but in the final model, we included only those
that significantly improved the model fit using the likelihood ratio
test. Age, sex, and propensity score for each drug were included in
the final model independent of the likelihood ratio test. We per-
formed a sensitivity analysis with a fully adjusted multivariate model
(see Supplementary Table S3 online).
We also checked the assumption, under the Poisson regression, of
the RR of infection compared with methotrexate remaining constant
over time by splitting the follow-up time into small intervals and
plotting the RR with a 95% CI for each drug in each of these time
units.
We calculated the number of patients needed for statistical power
to detect differences in comparison with methotrexate. We
computed a number needed to harm for one infection, one serious
infection, and one recurrent infection for each drug (see
Supplementary Table S4 online), by using raw rates of infection.
Adverse events were assigned to a drug if they occurred during
drug therapy or within a 90-day period after the last dose. If an
event could be associated with several drugs, it was associated with
all of them. We compared this method (90 days) with time from
discontinuation plus two half-lives of each drug, and the results
were virtually identical in the number of infections assigned to
each drug.
To analyze periods of exposure to more than one biological
drug, a new period of exposure called “combined exposure” was
created, and the infection was assigned to the combination therapy
group.
At least 78 events were required in both groups to detect a relative
risk of 2.0, assuming a power of 80% and alpha risk of 5%. Our
study had a power of greater than 80% to detect a 2-fold increase in
the risk of overall infection and recurrent infections. However, the
power to detect an RR of 2.0 in the rate of serious infections was less
than 60%.
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Table S1. Duration of follow up for each drug.  
F-U time: follow-up time in person-years. 
Sd: standard deviation. 
p25, p50, p75: Percentiles 25, 50 and 75 of the follow-up time. 
 
 
F-U time mean F-U time sd p25 p50 p75 
Etanercept 1228.6 1.67 1.80 0.45 0.97 2.09 
Infliximab 264.2 2.11 2.28 0.46 1.15 2.66 
Adalimumab 1329.7 1.87 1.86 0.51 1.17 2.67 
Ustekinumab 1194.0 2.22 1.79 0.70 1.68 3.56 
Metotrexate 1149.4 1.31 1.36 0.36 0.74 1.81 
Cyclosporine 250.6 0.59 0.70 0.21 0.35 0.71 
Acitretin 526.8 1.15 1.44 0.25 0.58 1.37 
Etanercep combined with mtx 284.7 1.91 1.82 0.61 1.32 2.53 
Infliximab combined with mtx 225.6 2.75 2.23 0.84 2.08 4.31 
Adalimumab combined with mtx 472.9 2.54 2.01 0.89 1.82 3.72 
Ustekinumab combined with mtx 340.2 2.70 1.91 1.02 2.31 4.29 
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Table S3. Sensitivity analysis of adjusted incidence risk ratio (RR) of infection 
compared to methotrexate.  
1. Adjusted for age, gender and propensity score of each drug compared to 
methotrexate. a. Additional adjustment for baseline Psoriasis Area Severity Index 
(PASI) and psoriasis arthritis.  b. Additional adjustment for disease duration. c. 
Additional adjustment for diabetes and history of tuberculosis.  
2. Adjusted for age, gender, propensity score of each drug compared to methotrexate, 
baseline Psoriasis Area Severity Index (PASI), psoriasis type, psoriasis arthritis, disease 
duration, diabetes, history of tuberculosis, ischemic cardiopathy, hypercholesterolemia, 
cancer in the last 5 years, chronic hepatopathy, hepatitis B, hepatitis C and HIV. 
* p<0.05 **p<0.01 
 
 
All RR adjusted (95% CI)1 Full-adjusted RR (95%CI)2 
Etanercept 1.34 (1.02-1.76)*a 1.39 (0.89-2.19) 
Infliximab 1.71 (1.1-2.65)* 2.36 (1-5.56)* 
Adalimumab 1.27 (0.92-1.75)b 1.08 (0.64-1.8) 
Ustekinumab 0.93 (0.64-1.36)c 0.68 (0.37-1.23) 
Metotrexate 1   
Cyclosporine 1.58 (1.17-2.15)** 1.58 (1.11-2.24)* 
Acitretin 0.6 (0.44-0.83)** 0.68 (0.51-0.9)** 
Etanercep combined with mtx 1.02 (0.52-1.99)a 1.35 (0.57-3.17) 
Infliximab combined with mtx 1.23 (0.68-2.23) 1.4 (0.64-3.09) 
Adalimumab combined with mtx 2.13 (1.23-3.67)**b 1.67 (0.74-3.78) 
Ustekinumab combined with mtx 1.56 (1.08-2.25)*c 1.5 (0.93-2.42) 
 
  
Table S4.1: Number needed to harm to have one infection compared to 
methotrexate. 
 
  Person-time Failures NNH 
Etanercept 1228.6 183 28 
Infliximab 264.2 56 10 
Adalimumab 1329.7 195 30 
Ustekinumab 1194 138 404 
Metotrexate 1149.4 130 - 
Cyclosporine 250.6 43 17 
Acitretin 526.8 34 -21 
Etanercep combined with mtx 284.7 31 -237 
Infliximab combined with mtx 225.6 25 -437 
Adalimumab combined with mtx 472.9 91 13 
Ustekinumab combined with mtx 340.2 56 19 
 
 
 
Table S4.2: Number needed to harm to have one serious infection compared to 
methotrexate. 
 
 
  Person-time Failures NNH 
Etanercept 1228.6 2 -126 
Infliximab 264.2 5 107 
Adalimumab 1329.7 13 4844 
Ustekinumab 1194 7 -270 
Metotrexate 1149.4 11 - 
Cyclosporine 250.6 5 96 
Acitretin 526.8 4 -506 
Etanercep combined with mtx 284.7 2 -393 
Infliximab combined with mtx 225.6 2 -1419 
Adalimumab combined with mtx 472.9 11 73 
Ustekinumab combined with mtx 340.2 3 -1330 
 
 
 
Table S4.3: Number needed to harm to have one recurrent infection compared to 
methotrexate. 
 
  Person-time Failures NNH 
Etanercept 1228.6 70 43 
Infliximab 264.2 21 22 
Adalimumab 1329.7 66 64 
Ustekinumab 1194 45 266 
Metotrexate 1149.4 39 - 
Cyclosporine 250.6 5 -72 
Acitretin 526.8 7 -48 
Etanercep combined with mtx 284.7 8 -171 
Infliximab combined with mtx 225.6 3 -48 
Adalimumab combined with mtx 472.9 38 22 
Ustekinumab combined with mtx 340.2 25 25 
 
Figure S1. Adjusted risk ratio (RR) of overall infection compared to methotrexate 
with 95% confidence interval. Vertical brown lines represent 95% Confidence Interval 
of adjusted incidence risk ratio of overall infections compared to Methotrexate. Blue 
dots represent adjusted incidence risk ratio of overall infections compared to 
Methotrexate. Horizontal red line represents and IRR=1 
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Abstract
Background Few reported studies compare drug survival in moderate-to-severe psoriasis vulgaris.
Objectives To describe and compare drug survival of systemic drugs, including biologic agents (inﬂiximab, etanercept,
adalimumab and ustekinumab) and classical drugs (acitretin, ciclosporin and methotrexate) in moderate-to-severe psori-
asis.
Methods This was a multicenter, prospective, cohort study of patients receiving systemic therapies between 2008 and
2013 in 12 hospitals in Spain. Baseline data and drug discontinuation were collected. Drug survival is presented using
Kaplan–Meier survival curves. We compared adjusted risk ratios of serious adverse events (AEs) with results of survival
analysis for AEs.
Results A total of 1956 patients were included for analysis (1240 exposed to biologics during follow-up and 1076 to
classic therapies). Median follow-up time was 3.3 years (0.0–5.1 years). There were 2209 discontinuations out of 3640
therapy cycles started. The main reason for discontinuation was lack of efﬁcacy (36.4%) and remission (27.2%). Biolog-
ics showed a higher drug survival than classics and the pattern of survival results for all outcomes (positive or negative)
were very similar. Adjusted risk ratios of serious AEs did not agree with results of survival analysis.
Limitations A limitation is that this is an observational study with potential selection bias.
Conclusion Survival as a proxy measure of drug safety in psoriasis is inadequate.
Received: 23 December 2015; Accepted: 22 February 2016
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Introduction
Biologic agents appear as an effective, well-tolerated and safe
therapeutic alternative to classic drugs such as ciclosporin,
methotrexate or acitretin as shown in randomized clinical trials
(RCT) in patients with moderate-to-severe psoriasis. However,
there are long-term safety concerns, as well as uncertainties
about its effectiveness in daily clinical practice and with patients
who have different characteristics other than those recruited in
RCT,1 that need to be answered.
Drug survival is defined as the duration of a specific therapy.
It has been used in different settings (e.g. rheumatoid arthritis
and psoriatic arthritis)2–5 as a proxy marker of overall therapy
effectiveness, as its results are related to efficacy, side-effects and
patient satisfaction.6 There is a growing interest in the descrip-
tion of survival of systemic drugs used for psoriasis.6–9
The main objective of this study was to describe and compare
drug survival of different biologic (infliximab, etanercept, adali-
mumab and ustekinumab) and classic (ciclosporin, methotrex-
ate, acitretin) systemic agents in psoriasis as a proxy measure for
effectiveness and safety. To check the value of survival analysis
to measure safety we compared the results of survival analysis
for adverse events (AEs) with raw and adjusted risk ratios of seri-
ous AEs.
Methods
This study is based on data from the Spanish registry of systemic
therapy in psoriasis (BIOBADADERM), a multicentre, prospec-
tive, cohort study in clinical practice. Biobadaderm has been
previously described.1,10,11 All patients gave their informed con-
sent to participate. The study has been approved by an ethics
committee and performed in compliance with the Declaration of
Helsinki and local regulations.
Twelve dermatology departments across Spain have partici-
pated. BIOBADADERM started in 2008. We included all
prospective data from January 2008 to October 2013. Biologics
†BIOBADADERM Study Group: This work was conducted within the group.
The following members participated in acquisition of data and review of the
manuscript: Beatriz P!erez Zafrilla PhD, BPharm (Unidad de Investigaci!on, Fun-
daci!on AEDV); Carlos Mu~noz-Santos, MD (Hospital Clinic of Barcelona, Barce-
lona); Victoria Mendiola-Fern!andez, MD, Cristina S!anchez Rold!an, MD (Hospital
Universitario Virgen de la Victoria, Malaga); Diana Ruiz-Genao, MD, Bego~na
Echeverr!ıa, MD (Hospital Universitario Fundaci!on Alcorc!on, Madrid); and
Sagrario Galiano Mej!ıas, MD (Hospital Universitario Infanta Leonor, Madrid,
Spain).
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have been commercially available in Spain since 2005. The
National Health System covers the cost of all study drugs.
All patients with moderate-to-severe psoriasis who started a
therapy with biologics (incident users for the specific drug) in
participating centres were included in Biobadaderm. As a com-
parison group, a systematic sample of psoriasis patients receiving
for the first time, a certain non-biological systemic therapy, was
collected, (i.e. next patient who first started methotrexate,
ciclosporin or acitretin after inclusion of a patient in the biolog-
ics group, but they may have received other classic systemic ther-
apy previously). Once patients on this group receive a biologic
drug, they move to the biologics group.
The only exclusion criterion was the patient’s refusal to
participate. Patient follow-up continued as long as possible. All
participants were monitored at least once a year but usually
several visits during a year were made as a part of usual care.
Table 1 Characteristics of patients who received the different drugs. Patients who have received several drugs are included in each col-
umn. Total number of patients is 1956
Etanercept Inﬂiximab Adalimumab Ustekinumab Acitretin Ciclosporin Methotrexate
Demographic data
Number of patients, n (%) 534 (100) 166 (100) 598 (100) 440 (100) 340 (100) 356 (100) 638 (100)
Number of cycles, n (% of all treatments) 672 (18) 181 (5) 724 (19) 491 (13) 406 (11) 401 (11) 765 (20)
Number of cycles that represent ﬁrst use
of the drug (% of all cycles)
373 (56) 88 (49) 299 (41) 161 (33) 235 (58) 237 (59) 454 (59)
Women, n (%) 218 (41) 59 (35) 224 (38) 185 (42) 107 (31) 174 (49) 285 (45)
Age, years (SD) 50 (14) 48 (12) 47 (13) 48 (14) 55 (16) 43 (14) 49 (15)
Duration of disease at start of
treatment, years (SD)
18 (13) 19 (12) 18 (11) 19 (12) 16 (16) 15 (12) 16 (13)
PASI, mean (SD) 13 (9) 18 (12) 13 (9) 15 (10) 9 (6) 13 (9) 9 (6)
Diagnosis at registration in cohort, n (% of total)
Plaque psoriasis 515 (96) 152 (92) 565 (94) 412 (94) 298 (88) 317 (89) 594 (93)
Other forms† 25 (5) 17 (10) 33 (6) 25 (6) 52 (15) 39 (11) 51 (8)
Psoriatic arthritis 105 (20) 35 (21) 120 (20) 65 (15) 18 (5) 25 (7) 74 (12)
Comorbidities, n (% of total patients)
Ischaemic cardiopathy 17 (3) 2 (1) 10 (2) 9 (2) 18 (5) 4 (1) 16 (3)
Arterial hypertension 113 (21) 33 (20) 125 (21) 96 (22) 101 (30) 40 (11) 149 (23)
Diabetes 61 (11) 25 (15) 65 (11) 50 (11) 56 (16) 27 (8) 63 (10)
Hypercholesterolaemia 126 (24) 40 (24) 154 (26) 116 (26) 109 (32) 72 (20) 183 (29)
Cancer in the last 5 years‡ 0 (0) 1 (1) 1 (0) 1 (0) 8 (2) 0 (0) 3 (1)
Chronic hepatopathy 44 (8) 15 (9) 34 (6) 25 (6) 13 (4) 18 (5) 11 (2)
Hepatitis B or C 49 (9) 12 (7) 30 (5) 19 (4) 30 (9) 16 (5) 27 (4)
HIV 5 (1) 1 (1) 5 (1) 6 (1) 6 (2) 3 (1) 2 (0)
Number of prior classic treatments, n (% of total patients)
0 99 (19) 36 (22) 103 (17) 60 (14) 183 (54) 164 (46) 327 (51)
1 144 (27) 34 (20) 148 (25) 111 (25) 82 (24) 101 (28) 166 (26)
2 or 3 241 (45) 73 (44) 278 (46) 211 (48) 66 (20) 75 (21) 125 (20)
4 or more 50 (9) 23 (14) 69 (12) 58 (13) 9 (3) 16 (5) 20 (3)
Prior classic treatments, n (% of total patients)
Phototherapy§ 274 (51) 82 (49) 307 (51) 270 (61) 91 (27) 109 (31) 209 (33)
Methotrexate 240 (45) 78 (47) 311 (52) 227 (52) 63 (19) 78 (22) *
Ciclosporin 209 (39) 75 (45) 263 (44) 188 (43) 46 (14) * 96 (15)
Acitretin 161 (30) 53 (32) 174 (29) 144 (33) * 56 (16) 109 (17)
Number of cycles with simultaneous administration of other systemic drug (n, % of all cycles)
Methotrexate 46 (7) 51 (28) 82 (11) 35 (7) 2 (0.5) 5 (1.3) *
Ciclosporin 18 (2.7) 5 (2.8) 34 (4.7) 14 (2.9) 3 (0.7) * 11 (1.4)
Acitretin 12 (1.8) 5 (2.8) 12 (1.7) 14 (2.9) * 5 (1.3) 8 (1.1)
*Non-applicable.
†Other forms of psoriasis: Erythrodermic psoriasis, Generalized pustular psoriasis, Palmoplantar pustulosis, Annular pustular psoriasis and Acrodermatitis
continua of Hallopeau; ‡Excluding non-melanoma skin cancer; §Including PUVA therapy and UVB (broad and narrow) therapy.
PASI, Psoriasis Area Severity Index; HIV, Human immunodeﬁciency virus; PUVA, psoralen + Ultraviolet A; UVB, Ultraviolet B; SD, standard deviation.
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Variables collected at entry were: age, gender, type of psoria-
sis, baseline PASI score, psoriasis arthritis, time from diagnosis,
previous treatments and comorbidities. As Biobadaderm is ori-
ented to safety, we did not collect measures of effectiveness dur-
ing therapy, but all serious AEs were registered in the database.12
Drug survival was calculated as time to first outcome: number
of days between the date when first dose was received and date
of the outcome. For patients without the study outcome, censor-
ing occurred at date of last dose given, last follow-up date in case
of losses to follow-up while on therapy, death or database down-
load date (20 October 2013), whichever occurred first. Drug
withdrawal was defined as two missing consecutive doses in the
patient’s current interdose interval. A treatment cycle was the
period of time from the start of a therapy to the last dose before
drug withdrawal.
The reasons for treatment termination were collected and
classified by the clinician : AEs, pregnancy or gestational desire,
remission, lack of efficacy or lower-than-expected improvement,
loss to follow-up and other. Lack of efficacy and remission were
not predefined and were described based on physician judge-
ment.
In order to improve data quality, once a year, a random sam-
ple of data were validated by on-site audits mainly focused on
measure of drug exposure and AEs, and review of the entire
record for a sample of patients. In case of inconsistency between
the documents, information from patient records was accepted
as true. This study received IRB approval from Hospital Univer-
sitario (12 de Octubre, 07/216).
Statistical analysis
Data were analysed using Stata 13.1 (StataCorp, 2013; Stata sta-
tistical software: College Station, TX, USA). Demographic and
descriptive data were presented as proportion in discrete quanti-
tative variables and as the mean and standard deviations in con-
tinuous quantitative data. We used patient-based analysis to
calculate the drug survival, instead of using cycle of treatment-
based analysis (i.e. the unit of analysis were patients, not cycles).
This means that, if a patient does not stop the therapy due to the
specific withdrawal reason under study, several cycles of therapy
(intermittent therapy) with the same drug were added up. In
cycle-based analysis, each new cycle wrongly starts counting the
time from zero. Patient-based analysis takes into account that
several cycles from the same patient are not independent, pro-
vides a more realistic description of the therapy, and is a fairer
way of comparing drugs that are used intermittently. Results of
drug survival were presented using Kaplan–Meier survival
curves. To compare survival curves we used log-rank test. We
used methotrexate as the comparator as it represents a standard
of therapy and the largest group among classic therapies. To
check the value of survival analysis as a proxy marker for more
relevant outcomes, we produced raw risk ratios of serious AEs,
and age and gender adjusted hazard ratios of serious AEs using
Cox regression and compared them with results of AEs survival
analysis.
Losses to follow-up were infrequent (less than 5% of follow-
up periods), as were missing data. Given the low number of
missing data, and expecting them to be at random, we dealt with
them analysing only available data.
Results
At the end of the follow-up period, 1956 patients were included
for analysis. Of them, 1240 were exposed to biologics and 1076
to classic therapies (some patients were exposed to both during
follow-up). Median follow-up time was 3.3 years (range: 0.0–
5.1 years. Follow-up of 0.0 years represent rounded follow-up
periods shorter than 18 days). Only 0.3% of patients declined to
participate.
Table 1 shows a description of baseline characteristics and
their distribution among drugs. Patients ever receiving biologics
had a higher proportion of women and higher prevalence of
Table 2 Observed number and causes of discontinuation among the different drug exposure groups during the follow-up time. Percent-
ages are done on the total of drug discontinuations, not on the total of drug cycles started. Differences that are signiﬁcant (P < 0.05) with
methotrexate using v2-test are in bold text
Reason for drug
discontinuation
Etanercept
n (%)
Inﬂiximab
n (%)
Adalimumab
n (%)
Ustekinumab
n (%)
Acitretin
n (%)
Ciclosporin
n (%)
Methotrexate
n (%)
Total
discontinuations
(%)*
Lack of efﬁcacy 188 (41.2) 52 (49.1) 182 (44.2) 64 (37.9) 96 (34.2) 86 (26.1) 137 (30.0) 805 (36.4)
Adverse event 55 (12.1) 25 (23.6) 52 (12.6) 13 (7.7) 40 (14.2) 58 (17.6) 79 (17.3) 322 (14.6)
Remission 122 (26.8) 9 (8.5) 105 (25.5) 50 (29.6) 77 (27.4) 109 (33.1) 128 (28.1) 600 (27.2)
Pregnancy or
gestational desire
7 (1.5) 3 (2.8) 11 (2.7) 5 (3.0) 0 (0.0) 6 (1.8) 12 (2.6) 44 (2.0)
Loss of follow-up 16 (3.5) 2 (1.9) 17 (4.1) 10 (5.9) 27 (9.6) 13 (4.0) 21 (4.6) 106 (4.8)
Other 68 (14.9) 15 (14.2) 45 (10.9) 27 (16.0) 41 (14.6) 57 (17.3) 79 (17.3) 332 (15.0)
Total discontinuations† 456 (100) 106(100) 412 (100) 169 (100) 281(100) 329 (100) 456 (100) 2209 (100)
*Number of discontinuations and percentages of each cause of discontinuation from all drugs during the following time in the BIOBADADERM registry.
†Total number of discontinuations of each drug.
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plaque type of psoriasis and psoriatic arthritis (v2 test P < 0.05).
PASI score at start of therapy, duration of disease at start of
treatment and number of previous treatments were also higher
in patients ever receiving biologics (t-Student, P < 0.05).
Number and causes of drug withdrawal
There were 2209 discontinuations from all causes during the
study period in 3640 treatment cycles (60.7% of cycles were dis-
continued). Causes of discontinuation are described in Table 2.
The most common cause was lack of efficacy (or lower-than-
expected improvement) followed by remission and AEs. Fifteen
per cent of all discontinuations that could not be classified in the
previous groups, are coded as ‘other causes’ and include admin-
istrative causes or pre-planned withdrawals.
Survival
Drug survival proportions, with calculated 95% confidence
interval, at first year for each drug are provided in Table 3.
Drug survival curves for the follow-up period are displayed in
Fig. 1.
Table 3 Drug survival probability (percentage and 95% of CI) at ﬁrst year, and survival times 25%, 50% and 75%. Survival time is the
time, in years, when the 25%, 50% and 75% of patients who had initiated the drug, stopped the treatment. 50% survival time is the med-
ian survival
Reason for drug
discontinuation
Drug survival probability
at ﬁrst year, % (95% CI)
Survival time
25% (years)
Survival time
50% (years)
Log-rank test of the comparison
with methotrexate, P-valuek
All causes†
Etanercept 55.5 (51.2–59.6) 0.52 1.21 0.13
Inﬂiximab 63.6 (55.7–70.5) 0.69 1.68 <0.001
Adalimumab 64.6 (60.6–68.3) 0.62 1.68 <0.001
Ustekinumab 79.4 (75.2–83.0) 1.25 ‡ <0.001
Acitretin 42.3 (36.9-47.6) 0.30 0.72 0.001
Ciclosporin 23.3 (19.0-27.8) 0.22 0.45 <0.001
Methotrexate 50.3 (46.3–54.2) 0.38 1.01 ‡
Lack of efﬁcacy¶
Etanercept 78.4 (74.4–81.9) 1.21 ‡ 0.05
Inﬂiximab 78.1(70.3–84.1) 1.18 ‡ 0.46
Adalimumab 79.5 (75.8–82.7) 1.29 ‡ 0.35
Ustekinumab 89.6 (86.2–92.3) ‡ ‡ <0.001
Acitretin 72.7 (66.8–77.7) 0.84 ‡ 0.004
Ciclosporin 67.8 (60.4–74.0) 0.71 2.30 <0.001
Methotrexate 79.6 (75.6–82.9) 1.69 ‡ ‡
Adverse event¶
Etanercept 92.6 (89.7–94.7) ‡ ‡ 0.02
Inﬂiximab 88.7 (82.1–92.9) ‡ ‡ 0.82
Adalimumab 93.8 (91.3-95.6) ‡ ‡ 0.003
Ustekinumab 98.8 (97.1-99.5) ‡ ‡ <0.001
Acitretin 88.7 (84.0–92.1) ‡ ‡ 0.86
Ciclosporin 78.5 (72.1–83.6) 1.64 ‡ <0.001
Methotrexate 87.8 (84.6-90.4) ‡ ‡ ‡
Remission§
Etanercept 85.5 (81.7–88.6) 2.15 ‡ 0.20
Inﬂiximab 96.1 (91.6–98.2) ‡ ‡ <0.001
Adalimumab 93.2 (90.5–95.1) 3.30 ‡ <0.001
Ustekinumab 95.4 (92.7–97.1) ‡ ‡ <0.001
Acitretin 79.0 (73.0–83.8) 1.28 ‡ 0.12
Ciclosporin 60.3 (53.4–66.5) 0.46 1.90 <0.001
Methotrexate 84.2 (80.4–87.3) 1.63 ‡ ‡
†All causes of drug discontinuation: Adverse event, pregnancy or gestational desire, remission, lack of efﬁcacy, loss to follow-up and other.
‡Non-applicable due to a lower percentage of discontinuations at the end of follow-up.
§Short survival is a positive result for remission.
¶Long survival is a positive result for the rest of outcomes.
kGiven that we are doing multiple comparisons, we suggest as a cut point for P-value signiﬁcance of P < 0.002 (Bonferroni correction for 24 comparisons).
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Overall, for all causes of discontinuations, most biologics
showed a superior drug survival rate at first year than classics
(Fig 1a). Ustekinumab had the highest survival rate at first year
(79.4%; 95% CI: 75.2-83.0) and ciclosporin the lowest (23.3%;
95% CI: 19.0-27.8). Within classics drugs, methotrexate showed
a better result (50.3%; 95% CI: 46.3-54.2) than acitretin and
ciclosporin (p = 0.001).
When lack of efficacy was the reason for discontinuing inter-
vention (Fig. 1b), ustekinumab showed the highest drug survival
throughout the 5 years of follow-up. Here, methotrexate had the
second higher survival followed closely by the other biologics
(anti-TNF drugs). Ciclosporin had the lowest survival of all
drugs.
When survival rate is analysed with AEs as reason for discon-
tinuing intervention, all drugs showed a higher survival, close to
0.75 along the 5 years of follow-up, with the isolated exception
of ciclosporin (Fig. 1c). Cyclosporin showed worse results than
methotrexate. Etanercept, adalimumab and ustekinumab
showed better survival than methotrexate.
When remission was the outcome of interest, a low survival is
a positive result. All biologics but etanercept, showed higher
survival than methotrexate. Ciclosporin had the highest risk for
discontinuation due to remission (Fig. 1d) and infliximab, the
lowest.
Focusing on when 25% of the patients on a drug stop the
treatment for any reason (see Table 3), ciclosporin had the
shortest period of time (0.22 years) and ustekinumab the longest
(1.25 years). Biologics presented longer periods for discontinua-
tion of the 50% of the initial patients (median survival range
from 1.21 to 1.68 years), compared to classics (range from 0.45
for ciclosporin to 1.01 of methotrexate).
Survival as a proxy for safety
We compared results of various methods to check survival as
proxy marker of serious AEs. We produced risk ratios of inci-
dence of serious AEs and Cox adjusted for age and gender haz-
ard ratios of serious AEs (Table 4). We think that this last
method represents the gold standard for measure of risk of AEs
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Figure 1 Drug survival rate for each drug separated into (a) all causes of discontinuation (b) lack of efﬁcacy and (c) adverse event as out-
come of interest. (d) shows the drug survival curve of each drug when remission is the outcome of interest (In this last graph low survival
is a positive result).
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in this paper. Results of Cox-adjusted hazard ratios did not agree
with survival analysis: only infliximab and cyclosporin showed
higher risks than methotrexate, and none of the drugs had a risk
lower than methotrexate.
Discussion
Our study confirms that survival of treatment in patients with
moderate-to-severe psoriasis decreases over time for all systemic
drugs included in the cohort, both classics and biologics.
Changes between drugs are common in psoriasis, and overall
biologic therapy lasts longer than classic therapy. Major reasons
for treatment discontinuation were lack of efficacy (36%), fol-
lowed by remission (27%). AEs accounted for 15% of with-
drawals. The pattern of drug survival results is very similar for
most causes of withdrawal (both positive and negative), with
some drugs always showing long survival and others always
showing short survival. Results of survival analysis for AEs con-
flict with raw and adjusted rates of serious AEs, suggesting that,
at least for safety, survival analysis is an unreliable proxy mea-
sure.
One of the strengths of the study is that the population
studied is highly representative of psoriasis patients in clinical
practice. Our study analyses data from large number of
patients from different hospitals around Spain and includes
patients who are not represented in clinical trials.1 Other
strengths are that we include data on classic drugs, use
patient-based analysis, and can compare survival safety results
with Cox-adjusted hazard ratios.
There are few studies comparing drug survival in patients
with psoriasis.6–9,13–17 As in our study, Gniadecki et al. based
their first study on data from a national database, Danish
DERMBIO. The major differences in relation to the present
study are that they did not include classical drugs or ustek-
inumab in the analysis, and did not report cause-specific sur-
vival. Our study obtained similar results in all-cause survival of
anti-TNF drugs: infliximab showed superior, but not significant,
survival rate compared with adalimumab and, adalimumab
higher than etanercept. However, the 4-year drug survival pro-
portions in our study were lower than the ones reported by
Gniardecki et al.: 30% vs. 70% for infliximab and 30% vs. 40%
for adalimumab and etanercept. Differences may be explained
by dissimilarities in baseline characteristic of patients who start
biologics between the registries, and different patterns of use in
the countries. Recently, Gniadecki et al. published a study on
long-term drug survival including retrospective and prospective
data from 2003 to 2013.16 It included data of ustekinumab and
used cycle-based analysis. This time they performed a sub-analy-
sis on discontinuations due to lack of efficacy, reporting similar
results.
The remaining studies describe drug survival only among the
anti-TNF drugs.7,9,14 The exception is a small single-centre
cohort study reported by Umezawa et al., which described
higher 1-year survival of ustekinumab, infliximab and adali-
mumab than the ones obtained in our study.8 A single study has
reported survival of fumaric acid esters without direct compar-
ison with other systemic therapies.13 None of these studies anal-
ysed survival rates separately by reason for discontinuation and
remission as a cause of discontinuation.
Our study has some limitations. First, it is observational, and
can suffer from the effects of bias in the selection of treatments
for each patient. Drug prescription was not at random, but
reflection of common use, leading to groups that were not com-
pletely similar at baseline and possible confounding by indica-
tion. Information bias in reporting of AEs or efficacy by
physicians or patients is also possible. To avoid it we used stan-
dardized definitions of AEs that should be reported, frequent
training of data collectors and data monitoring. We did not take
into account dose modifications (intensification or deintensifi-
cation) during the study, simultaneous use of biologics and clas-
sic drugs (these patients were considered as exposed to the
biologic), or whether the drug was the first drug to be used or
not. These modifications might affect survival.
Causes of drug discontinuation include positive causes (such
as remission) and negative causes (such as AE, or lack of effi-
cacy) of withdrawal. There are also a 15% of discontinuations
that cannot be classified in previous groups. They include
administrative causes or pre-planned withdrawals. If they are all
grouped together, as in previous publications, overall results are
Table 4 Comparison of results of survival due to adverse events with crude risk ratios and adjusted hazard ratios of serious adverse
events. Statistically signiﬁcant differences are marked in bold. Column on the right represent the best results to measure safety
1-year survival due to
adverse events
Log-rank test of the
comparison with
methotrexate, P-value
Crude risk ratio of serious
adverse events
Age and gender-adjusted
hazard ratio of serious
adverse events (Cox regression)
Ciclosporin 78.5 (72.1–83.6) <0.001 2.9 (1.8–4.6) 3.7 (1.6–8.8)
Methotrexate 87.8 (84.6–90.4) 1 1 1
Acitretin 88.7 (84.0–92.1) 0.86 2.5 (1.5–3.5) 1.4 (0.6–3.0)
Inﬂiximab 88.7 (82.1–92.9) 0.82 2.2 (1.4–3.5) 3.6 (1.6–8.2)
Etanercept 92.6 (89.7–94.7) 0.02 1.2 (0.8–1.9) 1.1 (0.6–2.0)
Adalimumab 93.8 (91.3–95.6) 0.003 1.6 (1.1–2.2) 1.8 (1.0–3.4)
Ustekinumab 98.8 (97.1–99.5) <0.001 1.2 (0.8–1.8) 1.2 (0.6–2.7)
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difficult to understand. However, we think that the main limita-
tion of our study, and of those based on survival analysis, is that
these results suffer from biases associated with the use of survival
as a proxy outcome for effectiveness or safety. As shown in
Table 4, results of safety using survival analysis do not agree with
results using raw and Cox-adjusted hazard ratios, that we con-
sidered a more straightforward and unbiased method. These dif-
ferences can be explained by some of the drawbacks of survival
analysis that we describe in Table 5.
All drug survival studies have drug discontinuation as out-
come of interest. However, most papers on the subject do not
define drug discontinuation, an issue that becomes especially rel-
evant with intermittent therapy and use of low doses.
Using one or several missing doses as definition of drug with-
drawal means that drugs with long dosing intervals have a more
difficult to achieve definition of withdrawal, compared with
other biologics or classic drugs. If an AE is resolved during the
interdose time, it might not cause treatment discontinuation
and this will be more probable if the period between doses is
longer.
Furthermore, a major drawback is that the threshold for drug
withdrawal is not fixed, but changes between drugs, patients and
over time, depending on factors unrelated to effectiveness or
safety (Table 5).
Changes between drugs are common in psoriasis, and overall
biologic therapy lasts longer than classic therapy. However, there
Table 5 Issues with survival analysis as a proxy measure for effectiveness and safety in psoriasis
Issues Explanation Comments
Not the best research question ‘What drug lasts longer?’ instead of ‘what
drug is safer or more effective?’
Patients and clinicians should focus on the second question, especially
if evidence for the advantages of continuous therapy is lacking. However,
many psoriasis studies do not have prospective effectiveness data or
control groups to describe safety, and for these studies survival might be
the only feasible alternative.
The event of interest studied in
survival analysis is drug withdrawal
and its deﬁnition is not
straightforward
Deﬁnition should take intermittent use
and short-term interruptions into account.
Most published papers do not include a deﬁnition of drug withdrawal so
their results are difﬁcult to understand and compare.
We used two missing doses at current dosing.
No clear alternative deﬁnitions for drug withdrawal.
All causes of drug withdrawal
should not be grouped
Causes of drug discontinuation include
positive causes (such as remission) and
negative causes (such as AE or
lack of efﬁcacy). ‘Other causes’ can be
difﬁcult to decipher and
represent 15% of causes.
Most published papers report results for ‘all causes of discontinuation’
Deﬁnition of drug withdrawal is
different between drugs
If missing doses of the drug are used for
deﬁning withdrawal, drugs with
long dosing intervals have more difﬁcult to
achieve deﬁnition of withdrawal.
24 weeks without receiving ustekinumab to consider withdrawn
compared to 2 days for acitretin or 2 weeks for methotrexate. Interdose
outcomes less likely to be reﬂected in survival for long interdose intervals.
Threshold for drug withdrawal
changes over time and
leads to bias
Drug label modiﬁcations Etanercept was initially approved only for intermittent therapy while the
other biologics were approved for continuous therapy from the
beginning.23,24
Economic factors The price of the different drugs might affect the results if they make
withdrawal more likely for some drugs, and if economic restrictions
change over time.25
Options of biological drugs available
increased with time
Potential increase in discontinuations and changes over time that lead
to worse survival over time.
Threshold for drug withdrawal
changes over patients and
leads to bias
Previous clinical history of the patient
may also affect discontinuation
Previous response or previous AEs may condition the survival time of
the next drug as clinicians might be more prone to discontinue therapy
based on previous outcomes.26
Threshold for drug withdrawal
changes between drugs
Concerns about safety Classical therapies for psoriasis are used intermittently considering
organ speciﬁc toxicity. This could lower survival of classic drugs,
especially for ciclosporin.18,19 Biologic drugs seem to lack the long-term
toxicity and data from research suggest the use of continuous therapy.20
Reﬂecting clinical practice In plaque psoriasis, there is no evidence of potential prevention of
long-term damage under continuous approach and some physicians
might favour intermittent therapy when possible.
Not all drugs are used intermittently.21,22 This may explain our results
on inﬂiximab being the drug with higher survival when remission is the
outcome of interest, and falsely decrease the survival of etanercept,
especially if per-cycle analysis were done.
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are a high number of variables that can influence drug survival
in psoriasis treatment, and many are not at all related with effec-
tiveness or safety. Survival analysis is not a good proxy marker
for safety and might be also biased as a measure of effectiveness.
In our opinion, the best way to measure safety is to report AEs
rates and rate ratios in cohorts and the best way to evaluate
effectiveness is to measure specifically, effectiveness variables as
the outcome of interest in cohort studies.
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Drug Survival  Analysis  Is  Not a Good  Method for
Assessing the  Safety or  Effectiveness of Systemic
Therapies in Psoriasis!
El análisis  de  supervivencia  no  es un  buen  método  para evaluar  la  seguridad
o  la  efectividad  de los  tratamientos  sistémicos  en  psoriasis
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Dermatology  journals  have  recently  published  numerous
articles  using  drug survival  analysis,  which  assumes  that  a
drug  ‘‘surviving’’  longer  in treatment  will be  one  that  is  safer
and/or  more  effective.  Is this  actually  the  case?
Survival  analysis  involves  a series  of  statistical  techniques
to  study  time  until  the  occurrence  of  an event  of  interest.
Initially  that  event  was  death,  hence  the name,  and  death
continues  to  be  the endpoint  in many  studies.  However,  the
application  of  survival  analysis  has  broadened  to  make  room
for  the  study  of  time  elapsing  between  many  types  of events.
One  recent  application  is  the study  of  drug survival,
defined  as  the  time  a patient  continues  to  take  a med-
ication.  This  concept  has  been  used  in various  chronic
diseases----rheumatoid  arthritis  for  example----as a  proxy  for
the  overall  effectiveness  of  a therapy,  given  survival’s  asso-
ciation  with  efficacy,  side  effects,  and  patient  satisfaction.
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o  la efectividad de los tratamientos sistémicos en psoriasis. Actas
Dermosifiliogr. 2017;108:3--5.
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We  now  have  a  growing  number  of  publications  describing
the  survival  of  systemic  treatments  for  moderate  to  severe
psoriasis.1--8 Why  has  this  type  of  analysis  emerged  in  this
setting?
In  our  opinion,  2 factors  are mainly  responsible  for these
studies.  The  first  is  the pressure  to  obtain  real-life  data  on
the  treatment  of psoriasis.  The  second  is that  survival  analy-
sis  requires  little  information,  merely  the  dates  for  starting
and  ending  treatment  and the reason for  withdrawing  the
drug.  There  is  no  need  for  a control  group  or  repeated  meas-
ures  of  clinical  variables.  Many  drug  survival  studies  have  no
control  groups  and do  not  measure  effectiveness,  preventing
them  from  using  other  approaches  to  obtain  more  significant
results.
Because  drug  survival  is  associated  with  many  variables,
however,  it is  difficult  to  interpret.  Comparisons  between
different  studies  or  different  drugs  are generally  impossible,
and  many  discrepant  findings  are generated.  We  will  discuss
some  of  the problems  these studies  present.
Although  defining  the  moment  treatment  stops  may  seem
straightforward,  in fact  it is  not.  Some  therapies  are  given
intermittently,  and  some regimens  include temporary  inter-
ruptions.  Many  studies  fail  to  state  how  the end  of  treatment
is  defined  while  others  indicate  that  a  treatment  has  stopped
1578-2190/© 2016 Elsevier Espan˜a, S.L.U. and AEDV. All  rights reserved.
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after  a  fixed  period  off treatment  or  a certain  number  of lost
doses.  Using  the loss  of one or  several  doses  as  the  definition
of  withdrawal  of a  drug  means  that  it is much  more  difficult
to  study  end  of treatment  with  medications  that  have  long
dosing  intervals  (such  as  infliximab  or ustekinumab,  which
are  given  at  intervals  of 8  and 12  weeks,  respectively)  than
it  is to  study  other  biologics  or  traditional  systemic  medi-
cations.  A patient  would  have to  be  off ustekinumab  for  24
weeks  before  treatment  could  be  said  to  have  stopped.  In
contrast,  withdrawal  of  treatment  with  acitretin  could  be
recorded  after 2  days  off treatment.  The  period  would  be  2
weeks  for  methotrexate  or  etanercept.
Another  important  aspect  to  consider  is  that  events
(thresholds  or  marker  cutoffs)  that  lead  to  suspending  a
treatment  differ  from  one  drug  to  another,  between  pre-
scribers,  between  patients,  and  over  time.
Thresholds  differ  from  drug  to  drug because  of  intervals
between  doses and  concerns  about  safety.  Clinical  practice
routines  also  play  a  role.  Suspension  of  treatment  due  to
adverse  effects  is  less  likely  to  occur when  there  is  a long
interval  between  treatments.  If the  patient  describes  a
problem  with  a drug whose  next  dose  is  to be  administered
months  later,  adverse  effects  that  have  long  passed  will
probably  not  have  much  influence  on  the decision  to  suspend
treatment  or  not.  In  contrast,  decisions  about  whether  or
not  to stop  a drug like  ciclosporin  that  is  taken  every  12  hours
will  have  to  be  made  daily,  so  adverse  events  are more  likely
to  lead  to  suspension.  These  factors  probably  lead  to  longer
survival  times  for ustekinumab  and infliximab.
Another  consideration  is  that  traditional  systemic  treat-
ments  for  psoriasis  are used intermittently  because  of
concerns  about  toxic effects  on  specific  organs  due  to  cumu-
lative  exposure.  The  best  example  of  a drug  prescribed
for  short  periods  of time  is  ciclosporin,  as  treatment  last-
ing  longer  than  a year  increases  the risk  of  adverse  effects
(nephrotoxicity).  In comparison  with  traditional  therapies,
biologics  do  not seem  to  present  a  problem  of  toxicity  over
the  long  term,  and current  research  suggests  that  continuous
therapy  improves  disease  control  and  quality  of  life.9 When
a  patient  is  started  on  a  biologic,  long-term  use  is  likely  to
be  assumed.
Approaches  to  treatment  are  different  in rheumatic  dis-
eases  and  psoriasis.  Optimal  control  of  inflammation  through
long-term  therapy,  in the  interest  of preventing  sequelae,
is  the  goal  in  rheumatic  diseases.  In  psoriasis,  there  is
insufficient  evidence  that  preventing  damage  over  the long
term  can  be  achieved  through  continuous  treatment.  This
uncertainty,  along  with  doubts  about  the long-term  safety
of  biologics  and  concerns  about  their  cost  can  lead some
prescribers  to prefer  intermittent  treatment  whenever  pos-
sible.
A  randomized  controlled  trial  showed  that  continuous
therapy  with  some drugs----such  as  infliximab----is  more  effec-
tive,  safer,  and  leads  to  fewer  serious  reactions  related  to
the  infusion.10 This  finding  may  explain  why  infliximab  sur-
vives  longer  than  other  inhibitors  of  tumor  necrosis  factor
(TNF)  in  some  trials,  especially  when  remission  is the  end-
point  of  interest.10,11
Criteria  for  interrupting  treatment  and  withdrawing  a
drug  can  also  vary  between  patients.  Prior  clinical  history
may  be  a  factor  in deciding  to  stop treatment.  It seems
reasonable  that  response  to  previous  therapies  or  adverse
effects  would  influence  the  survival  of drugs  tried  later,
especially  if they  share  a  chemical  structure  or  their  mech-
anisms  of  action  target  the  same  molecular  pathway.  For
example,  if a patient  does  not respond  well  to  one  anti-TNF
agent,  the  prescriber  may  tend  to  stop  another  such agent
tried  at a later  time  if  improvement  fails  to  come  as  quickly
as  expected.12
The  criteria  for  suspending  treatment  specified  in a  drug’s
summary  of product  characteristics  (SPC)  may  also  change
over  time.  Etanercept  was  the first  anti-TNF  agent  on  the
market  and its  SPC  has  changed  since  it  was  approved.
The  recommended  dosage  in 2006  was  25  mg  twice  weekly,
and  treatment  was  to  continue  until  remission  or  up  to
24  weeks.  If  retreatment  with  etanercept  became  neces-
sary,  the  old  recommendation  called  for  applying  the same
criteria  regarding  duration  of  therapy.13 However,  since
September  2009,  the  European  Medicines  Agency’s  label  for
etanercept  recognizes  the  possibility  of  extending  treat-
ment  beyond  24  weeks  for  some  adults,  and the decision  to
treat  intermittently  or  continuously  can  be tailored  to  the
individual  if the physician  considers  it necessary.14 Such  dif-
ferences  appearing  over  time  have  the potential  to  influence
etanercept’s  survival  rates  in comparison  with  other  bio-
logics  that  were  recommended  for  continuous  therapy  from
the  start if researchers  gather  data  from  registries  started
before  the SPC  changes.
Another  issue  to  consider  is  that  more  biologics  have
entered  the market  over time,  raising  expectations  of  effec-
tiveness.  This  situation  may  be leading  to  more  treatment
suspensions  in recent years,  as  patients  are  switched  to
another  drug.
Drug  costs  also  change  over  time,  possibly  affecting
the  survival  of drugs  used  to  treat  psoriasis.  Since  the
world  economic  crisis  began  in  2008,  the  Spanish  national
health  service  has tried to reduce  spending  on expensive
therapies15 through  measures  like requiring  prescriptions,
extending  the time  a patient  is  kept  on  certain  drugs  even
if  response  is  not optimal,  or  promoting  intermittent  use  or
switches  to  cheaper  medications.  All  such changes  distort
drug survival  analyses.
Yet  another  problem  with  drug  survival  studies  is  that  the
reasons  for  treatment  interruption  include  both  positive  out-
comes  (such  as  remission)  and negative  ones  (such  as  adverse
events  or  lack  of effectiveness).  We  also  see  a nonnegligi-
ble number  of  reasons  for  stopping  treatment  that  do not
fit  into  either  of  these  categories  and  that  are  difficult  to
interpret.  Some  15%  of  cases  in the  Biobadaderm  registry
involve  such  reasons.16 Some  drug survival  studies  group  all
reasons  for  suspension  together,  making  their  findings  even
more  difficult  to  grasp  and  compare.
Finally,  a  more  general  criticism  of  drug survival  anal-
ysis  in psoriasis  concerns  the very  research  question  being
asked  in  these  studies:  Is it truly  important  for patients  and
clinicians  to  know  which  treatments  survive  longer?  What  is
really  important  is  which  treatments  are  more  effective  or
safer.
In  summary,  we  believe  that  drug survival  studies  do
not  offer  a good  way  to  evaluate  the safety or  effective-
ness  of  psoriasis  treatments  and that  they  are  particularly
inappropriate  for  comparing  treatments.  In a recent  study
utilizing  Biobadaderm  registry  data  we  showed  that  drug  sur-
vival  used as  a proxy  indicator  of  safety  was  misleading.16
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The  best  way  to  measure  safety,  we  think, is  to  publish  the
rates  of  adverse  events  in  cohort  studies.  Effectiveness  is
best  demonstrated  through  experimental  or  observational
studies  in  which  effectiveness  is  specified  as  the outcome
measure.  Drug  survival  analysis,  with  all  its inherent  prob-
lems,  may  be of  interest  mainly  for  generating  models  to
assess  treatment  cost.
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PSONET is an international network of independent 
partners that aims to document “real-life” use of sys-
temic drugs for psoriasis in different countries (1–3). 
Differences in how the registries’ populations are treated 
have implications for the analysis of data (as these fac-
tors could act as confounders for risk estimates), for the 
generalizability of results from individual registries, and 
for understanding dermatologist behaviour in different 
healthcare systems and countries. 
The objective of this study is to describe and compare 
the characteristics of patients treated with classic and 
biological agents for psoriasis in participating registries.
METHODS 
The study population are patients with moderate-to-severe psoria-
sis, over 18 years of age, who have received systemic treatment 
for psoriasis. Except for Clalit Health Services, which utilizes 
administrative data, participating registries are cohort studies that 
enrol patients when they first receive, or are currently receiving, 
a study drug. 
Baseline data from 7 countries’ registries included the Nether-
lands (Academic Medical Centre (AMC) psoriasis registry) (4, 
5), Australia (Australasian Psoriasis Registry), Spain (BIOBA-
DADERM) (6, 7), Israel (The Clalit Health Services), Denmark 
(DERMBIO) (8, 9), Germany (PSOBEST) (10) and Italy (PSO-
CARE) (11, 12). 
Participating registries provided aggregated summary data 
concerning baseline, demographic and disease characteristics of 
their cohort. Table SI1 gives information about the organization of 
each registry. Inclusion criteria for the different registers are earlier 
described in (3). In general, they include all biological treatments 
consecutively and a convenience sampling of classic drugs. All 
registries received approval from their local ethics committee, 
and comply with the principles of the Declaration of Helsinki.
Statistical analysis
Pooled analyses were performed using Stata 12.1 software (Sta-
taCorp College Station, TX, USA). To measure the association 
between exposure to biologics or classic systemic therapies and 
a priori defined variables, differences in means between groups 
were used for continuous variables, and odds ratios (OR) for ca-
tegorical variables. To pool data from registries, forest plots were 
used and a random-effects meta-analysis was conducted to describe 
differences among groups exposed to biologics or conventional 
therapies. Pooled estimates of effects were produced if results 
were not too heterogeneous (I2 < 60%). Some registries were not 
able to provide data on all of the defined variables. Due to the lack 
of enrolment of patients receiving classic systemic therapy, AMC 
psoriasis registry data were not included in the forest plots and in 
comparisons of exposure cohorts. In all the other registries, if a 
patient began in the non-biological therapy group and subsequently 
received a biologic drug, his or her characteristics contributed to 
both groups in the analysis.
RESULTS
From the start of each registry to August 2012, a total 
of 20,232 patients had been enrolled in the registries 
and provided baseline information. This included 9,668 
(47.8%) initially treated with biologics and 10,564 
(52.2%) starting classic systemic therapies.
Demographic and disease characteristics are summa-
rized in Tables SII and SIII1. 
Some differences between patients receiving biologics 
and those receiving classic drugs were homogeneous 
between registries (I2 ≤ 60%). These are presented in 
forest plots in Fig. 1, which includes I2 values, and poo-
led estimates. Overall, patients on biologics were 0.42 
units of body mass index (BMI) heavier than those on 
classic systemic drugs (95% CI: 0.25–0.58). The OR of 
males vs. females receiving biologics was 1.08 (95% CI: 
0.94–1.24). Use of biologics was slightly less likely in 
current smokers (OR 0.89, 95% CI: 0.80–0.99). 
Fig. S11 shows the results in each registry, but not 
pooled estimates, because heterogeneity was too high 
(I2 > 60%). Age at entry, age at diagnosis and Psoriasis 
Area and Severity Index (PASI) at entry were too hete-
rogeneous among registries to be combined in the meta-
analysis. Italian and Spanish patients on biologics had a 
PASI significantly higher at entry and were significantly 
younger at diagnosis than those receiving classic syste-
mic therapies. Few registries reported measurements of 
body surface area (BSA) and Dermatology Life Quality 
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Index (DLQI) or SKINDEX, making comparisons be-
tween registries difficult. 
Patients with psoriatic arthritis or nail disease were 
more likely to receive biologics than classic therapies in 
almost all registries, but the results were heterogeneous 
despite the significant OR favouring the usage of biologics 
in most of them. In registries from Italy and Spain, pa-
tients with psoriasis different from plaque psoriasis were 
significantly more likely to receive conventional drugs. 
DISCUSSION
In agreement with the findings of a previous PSO-
NET analysis (1), the current study revealed that wide 
between-country heterogeneity exists in the distribution 
of covariates potentially influencing treatment selec-
tion (e.g. age, PASI and proportion with non-chronic 
plaque psoriasis). Beyond between registry variability, 
the current study found that some covariates are related 
per se with the odds of receiving a biologic or a classic 
treatment in most registries, e.g. BMI, psoriatic arthritis, 
nail disease or proportion of current smokers. 
The strengths of this study are the increased power 
obtained from multiple registries compared with using 
each separately, the ability to describe and quantify 
between-country differences, and the use of a meta-
analytical approach, in which each registry acts as its 
own control, which limits the risk of biases related to 
differences between registries. In addition, meta-analysis 
is a good way to define and quantify heterogeneity and 
to balance out differences in sizes among the registries. 
Study limitations are: missing data from some regist-
ries, missing data on some predefined variables and that 
only univariate analysis was performed and we could not 
rule out that the factors we found as being associated with 
treatment choices were, in fact, intercorrelated and not 
independently associated with the treatment selection. A 
further limitation is that we could only analyse commonly 
measured and coded variables. Finally, the data were not 
updated. This delay is due to the extreme difficulty in 
combining data from different national registries. But 
because of the already high number of participants, we 
consider that this should not affect the results and overall 
conclusions. 
Methodological differences might explain some of 
the differences found. This is probably the case for 
the heterogeneity of the percentage of patients with 
psoriatic arthritis or in PASI values. PASI values are 
also influenced by the lack of wash-out periods before 
starting a new therapy (leading to variability and PASI 
decrease) in real-world registries and by the fact that 
a minimum PASI is mandatory to prescribe biologics 
in some countries (possibly leading to a factitious in-
crease). Single outlying results may also hide otherwise 
homogenous effects, e.g. only in the Danish registry is 
there no greatly increased use of biologics for psoriasis 
arthritis; thus, the otherwise highly significant prediction 
by psoriasis arthritis disappears.
Conclusion
Knowledge of the factors related to drug selection is 
important in order to plan statistical analysis of observa-
tional data (13). Each registry could use this information 
to develop strategies for dealing with prescription bias, 
using methods such as propensity scores (14). Identifi-
cation of differences in the international usage of drugs 
can be useful for interpretation of observational studies 
(e.g. generalization of results) (15), adds knowledge and 
understanding of different healthcare systems and might 
indicate areas for improvement in patient management. 
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Fig. 1. Forest plot showing the overall result in psoriasis 
characteristics of patients without substantial heterogeneity 
(I2<60%) in both biologic and control group among different 
registries: (a) differences in body mass index (BMI) between biologic 
and conventional treatment groups. (b) Odds ratio (OR) of biologic use 
compared with conventional treatment among current smokers. (c) OR 
of biologic use compared with conventional treatment among current 
drinkers.
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Fig. S1. Forest plot showing the overall result in psoriasis 
characteristics of patients with substantial heterogeneity (I2>60%) 
in both biologic and control group among different registries. The 
main differences are found between biologic and conventional treatment 
groups of psoriasis in: (a) age at entry, (b) age at diagnosis, (c) Dermatology 
Quality of Life Index (DLQI), (d) Psoriasis Area Severity Index (PASI), (e) 
body surface area affected (BSA) and the odds ratio (OR) of biologic use 
compared with conventional treatment among (f) male patients, (g) patients 
with psoriatic arthritis, (h) patients with psoriasis different from chronic 
plaque psoriasis, and (i) with nail disease.
NOTE: Weights are from random effects analysis
Overall  (I−squared = 74.9%, p = 0.001)
Psocare, Italy
ID
Biobadaderm, Spain
Dermbio, Denmark
PsoBest, Germany
Study
Australian Psoriasis Registry
Clalit Health Service, Israel
−0.32 (−1.55, 0.90)
−1.29 (−1.83, −0.76)
WMD (95% CI)
−2.08 (−3.59, −0.58)
2.08 (−0.12, 4.29)
1.49 (−0.12, 3.11)
−0.88 (−6.52, 4.77)
−0.71 (−2.05, 0.64)
100.00
  24.96
Weight
18.80
14.23
18.04
%
4.02
19.95
  0−6.52 6.52
Higher in classics                      Higher in biologics
Mean difference between biologic and control group in age (a)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 84.4%, p = 0.000)
Clalit Health Service, Israel
Psocare, Italy
ID
Study
Biobadaderm, Spain
Australian Psoriasis Registry
PsoBest, Germany
Dermbio, Denmark
−2.11 (−3.82, −0.41)
−1.21 (−2.55, 0.13)
−4.00 (−4.60, −3.40)
WMD (95% CI)
−4.46 (−6.10, −2.82)
−1.00 (−8.17, 6.17)
−1.00 (−2.78, 0.78)
0.92 (−1.88, 3.71)
100.00
20.44
22.76
Weight
%
 19.24
4.55
18.65
14.36
  0−8.17 8.17
Higher in classics                      Higher in biologics
Mean difference between biologic
and control group in age at diagnosis
(b)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 87.3%, p = 0.000)
PsoBest, Germany
Australian Psoriasis Registry
Study
ID
Dermbio, Denmark
−0.40 (−3.81, 3.00)
1.47 (0.61, 2.33)
−2.27 (−17.03, 12.49)
WMD (95% CI)
−2.22 (−3.83, −0.61)
100.00
49.40
4.82
%
Weight
45.78
  
0−17 17
Higher in classics                      Higher in biologics
Mean difference between biologic and control group in DLQI (c)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 95.7%, p = 0.000)
Dermbio, Denmark
Study
PsoBest, Germany
Biobadaderm, Spain
Psocare, Italy
Australian Psoriasis Registry
ID
2.14 (−0.41, 4.69)
−1.56 (−3.11, −0.01)
0.64 (−0.56, 1.84)
6.24 (5.26, 7.22)
2.14 (1.67, 2.61)
5.33 (−3.14, 13.80)
WMD (95% CI)
100.00
22.41
%
23.18
23.58
24.23
6.61
Weight
  0−13.8 13.8
Higher in classics                      Higher in biologics
Mean difference between biologic and control group in PASI (d)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 100.0%, p = .)
PsoBest, Germany
ID
Study
2.67 (0.17, 5.17)
2.67 (0.17, 5.17)
WMD (95% CI)
100.00
100.00
Weight
%
  
0−5.17 5.17
Higher in classics                      Higher in biologics
Mean difference between biologic and control group in bsa
(e)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 57.8%, p = 0.037)
Psocare, Italy
Clalit Health Service, Israel
Dermbio, Denmark
Biobadaderm, Spain
Study
ID
PsoBest, Germany
Australian Psoriasis Registry
1.08 (0.94, 1.24)
1.07 (0.99, 1.16)
0.82 (0.69, 0.98)
1.26 (0.90, 1.77)
1.23 (0.99, 1.52)
OR (95% CI)
1.21 (0.95, 1.53)
1.06 (0.48, 2.34)
100.00
30.50
21.08
10.91
18.28
%
Weight
16.55
2.69
  1.427 2.34
Higher in classics                      Higher in biologics
OR of biologic use for male patients (f)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 94.4%, p = 0.000)
Biobadaderm, Spain
Study
ID
Australian Psoriasis Registry
PsoBest, Germany
Psocare, Italy
Dermbio, Denmark
2.38 (1.40, 4.06)
2.35 (1.66, 3.31)
OR (95% CI)
2.08 (0.87, 4.97)
4.88 (3.72, 6.40)
3.44 (3.13, 3.77)
0.85 (0.60, 1.20)
100.00
20.84
%
Weight
14.19
21.54
22.65
20.78
  1.156 6.4
Higher in classics                      Higher in biologics
OR of biologic use for patients with arthritis (g)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 62.7%, p = 0.045)
Study
PsoBest, Germany
Dermbio, Denmark
Psocare, Italy
ID
Australian Psoriasis Registry
1.36 (1.06, 1.74)
1.72 (1.36, 2.19)
0.84 (0.50, 1.39)
1.45 (1.34, 1.56)
OR (95% CI)
0.77 (0.28, 2.10)
100.00
%
32.98
15.70
46.03
Weight
5.29
  1.282 3.54
Higher in classics                      Higher in biologics
OR of biologic use for patients with nail disease (h)
NOTE: Weights are from random effects analysis
Overall  (I−squared = 65.0%, p = 0.022)
Psocare, Italy
ID
Dermbio, Denmark
Biobadaderm, Spain
PsoBest, Germany
Australian Psoriasis Registry
Study
0.77 (0.55, 1.07)
0.72 (0.65, 0.79)
OR (95% CI)
2.14 (1.02, 4.48)
0.50 (0.33, 0.75)
0.73 (0.47, 1.14)
0.80 (0.18, 3.59)
100.00
35.90
Weight
13.29
23.92
22.46
4.42
%
  1.179 5.59
Higher in classics                      Higher in biologics
OR of biologic use for patients with psoriasis
different from chronic plaque form
(i)
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
Acta Derm Venereol 2017
Supplementary material to article by P. Davila-Seijo et al. ”Factors Associated with Receiving Biologics or Classic Systemic Therapy for 
Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries”
Table SI. Description of participating registriesa 
Registry name, country
AMC psoriasis registry, 
Netherlands
Australasian Psoriasis 
Registry, Australia
Biobadaderm, 
Spain
Clalit Health 
Service, Israel
Dermbio, 
Denmark
PsoBest, 
Germany
Psocare, 
Italy
Registry started, yearb 2008 2008 2008 2007 2007 2008 2005
Centres participating in registrya, n 1 10 13 3,500 5 hospital, 10 
private
530 
hospital 
and private
164
Patients registered on biologics 194 475 793 554 1083 378 6,191
Patients registered on classic 
systemic drugs
0 29 632 3,204 161 1,167 5,371
Population of country (millions)a 16 22 46 7.7 6 81 70
Estimated % of the population 
sampled by each registrya*
0.05% 0.05% <10% 100% >90% 10% 80%
*Percentage is calculated with all patients included in each registry.
aAdapted from from García-Doval et al (1). The Academic Medical Center (AMC) psoriasis registry does not have a control group receiving classic therapy. Registry 
enrolment of patients receiving biologics was compulsory in Denmark and Italy. Clalit Health Services data were abstracted from computerized patient records of this 
health maintenance organization. In the Australasian Psoriasis Registry, with the exception of infliximab, is there no requirement for attempting previous classic systemic 
therapy. Dermbio registry added retrospectively available data for biologic treatments that had been initiated before the launch of the Danish registry. bData obtained 
from Ormerod et al. (3).
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Table SII. Demographic baseline characteristics of patients with psoriasis in both biologic 
and control group among different registries
Demographics
Biologics Classic drugs
Patients
n Mean (95% CI)
Patients
n Mean (95% CI)
Mean age 
  AMC psoriasis registry, The Netherlands 194 50.6 (48.8–52.4) NA NA
  Australian Psoriasis 475 49.8 (48.6–51.0) 29 50.7 (45.2–56.2)
  Biobadaderm, Spain 793 43.9 (42.9–44.8) 632 45.9 (44.8–47.12)
  Clalit Health Service, Israel 554 52.3 (51.1–53.5) 3,204 53.0 (52.4–53.6)
  Dermbio, Denmark 1,083 45.3 (44.5–46.1) 161 43.2 (41.2–45.3)
  PsoBest, Germany 378 48.4 (47.0– 49.8) 1,167 46.9 (46.1–47.8)
  Psocare, Italy 6,191 47.8 (47.5–48.2) 5,371 49.1 (48.7–49.5)
Percentage of males 
  AMC psoriasis registry, The Netherlands 120 61.9 (55.0–68.7) NA NA
  Australian Psoriasis 319 66.9 (62.7–71.1) 19 65.5 (48.2–82.8)
  Biobadaderm, Spain 502 63.3 (59.9–66.7) 369 58.4 (54.5–62.2)
  Clalit Health Service, Israel 286 51.6 (47.5–55.8) 1,811 56.5 (54.8–58.2)
  Dermbio, Denmark 686 63.3 (60.5–66.2) 93 57.8 (50.1–65.4)
  PsoBest, Germany 235 61.8 (57.0–66.7 1,811 57.3 (54.4–60.1)
  Psocare, Italy 4,173 67.4 (66.2–68.6) 3,535 65.8 (64.5–67.1)
Percentage of current drinkers 
  Australian Psoriasis 227 74.2 (69.3–79.1)   7 63.6 (35.2–92.1)
  Biobadaderm, Spain 176 28.8 (25.2–32.4) 153 31.1 (27.0–35.2)
  PsoBest, Germany   19   5.0 (2.8–7.2) 45   3.8 (2.7–4.9)
  Psocare, Italy 2,160 34.9 (33.7–36.1) 1,962 36.5 (35.2–37.8)
Percentage of current smokers
  Australian Psoriasis   30 10.5 (7.0–14.1)   1 33.3 (–20.0–86.7)
  Biobadaderm, Spain 232 35.7 (32.1–39.4) 228 41.8 (37.6–45.9)
  Clalit Health Service, Israel 137 24.7 (21.1–28.3) 862 27.2 (25.7–28.8)
  PsoBest, Germany 146 38.4 (33.5–43.3) 507 43.3 (40.5–46.2)
  Psocare, Italy 2,357 38.1 (36.9–39.3) 2,101 39.1 (37.8–40.4)
Mean body mass index
  AM, psoriasis registry, The Netherlands 167 28.7 (27.7–29.7) NA NA
  Australian Psoriasis 367 29.2 (28.4–30.0) 24 30.0 (27.4–32.6)  
  Biobadaderm, Spain 626 27.9 (27.5–28.4) 537 27.6 (27.2–28.0)
  Clalit Health Service, Israel 548 30.5 (28.7–32.3) 3,141 29.1 (28.6–29.6)
  Dermbio, Denmark 404 28.9 (28.1–29.7) 50 27.4 (25.9–28.9)
  PsoBest, Germany 379 28.3 (27.8–28.8) 1,163 27.9 (27.5–28.3)
  Psocare, Italy 5,869 27.2 (27.1–27.3) 5,138 26.8 (26.7–26.9)
CI: confidence interval; NA: not available; AMC: Academic Medical Center.
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Table SIII. Disease-related variables of patients with psoriasis in both biologic and control 
group among different registries
Characteristics of psoriasis
Biologics Conventional treatment
Patients
n Mean (95% CI)
Patients 
n Mean (95% CI)
Mean age at diagnosis 
  AMC psoriasis registry, The Netherlands 189 25.1 (23.2–27.1)   NA NA
  Australian Psoriasis 337 26.0 (24.5–27.5)   20 27.0 (20.0–34.0)
  Biobadaderm, Spain 786 25.3 (24.3–26.3) 629 29.8 (28.5–31.1)
  Clalit Health Service, Israel 554 49.8 (48.6–51.1) 3,204 51.0 (50.5–51.6)
  Dermbio, Denmark 901 27.2 (26.2–28.2)    133 26.3 (23.7–28.9)
  PsoBest, Germany 349 28.0 (26.5–29.5) 1,100 29.0 (28.0–30.0)
  Psocare, Italy 6,006 30.0 (29.6–30.4) 5,215 34.0 (33.5–34.5)
Percentage with psoriasis different from plaque psoriasis 
  Australian Psoriasis   22   5.6 (3.3–7.9)     2   6.9 (–2.3–16.1) 
  Biobadaderm, Spain   41   5.2 (3.6–6.7)   62   9.8 (7.5–12.1)
  Dermbio, Denmark 109 10.1 (8.3–11.9)     8   5.0 (1.6–8.3)
  PsoBest, Germany   26   6.8 (4.3–9.4) 107   9.1 (7.5–10.8)
  Psocare, Italy 829 13.4 (12.5–14.2) 953 17.7 (16.7–18.8)
Percentage with arthritis
  AMC psoriasis registry, The Netherlands   50 27.6 (21.1–34.1)   NA NA
  Australian Psoriasis 190 39.8 (35.4–44.2)     7 24.1 (8.6–39.7)
  Biobadaderm, Spain 133 16.8 (14.2–19.4)   50   7.9 (5.8–10.0)
  Dermbio, Denmark 337 31.1 (28.4–33.9)   56 34.8 (27.4–42.1)
  PsoBest, Germany 150 39.5 (34.6–44.4) 138 11.8 (9.9–13.6)
  Psocare, Italy 2,170 35.1 (33.9–36.2) 729 13.6 (12.7–14.5)
Percentage with nail disease 
  Australian Psoriasis   71 14.9 (11.7–18.1)     5 18.5 (3.9–33.2)
  Dermbio, Denmark 115 10.6 (8.8–12.5)   20 12.4 (7.3–17.5)
  PsoBest, Germany 64.2 (59.4–69.0) 51.0 (48.2–53.9) 
  Psocare, Italy 2,591 41.9 (40.6–43.1) 1,785 33.2 (32.0–34.5)
Mean Psoriasis Area and Severity Index 
AMC psoriasis registry, The Netherlands 173 14.5 (13.5–15.5)   NA NA
Australian Psoriasis 423 30.8 (29.0–32.6)   11 25.5 (17.2–33.7)
Biobadaderm, Spain 613 16.5 (15.7–17.3) 478 10.3 (9.7–10.9)
Dermbio, Denmark 848 10.8 (10.2–11.4) 134 12.4 (10.9–13.8)
PsoBest, Germany 370 15.3 (14.3–16.4) 1,140 14.7 (14.2–15.2)
Psocare, Italy 4,505 18.5 (18.2–18.9) 3,977 16.4 (16.1–16.7)
Mean body surface area 
AMC psoriasis registry, The Netherlands 167 18.1 (15.8–20.4)     NA NA
PsoBest, Germany 374 26.9 (24.7–29.1) 1,126 24.2 (23.1–25.4)
Mean Dermatology Life Quality Index 
Australian Psoriasis   99 17.2 (15.9–18.6)     2 19.5 (4.8–34.2)
Dermbio, Denmark 595 10.2 (9.6–10.8)   87 12.4 (10.9–13.9)
PsoBest, Germany 370 12.5 (11.7–13.2) 1,146 11.0 (10.6–11.4)
CI: confidence interval; NA: not available; AMC: Academic Medical Center.
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7.2 Article 5. Registries as real-world cohort studies 
that are useful and necessary in the pyramid of 
evidence 
  
Analysis of survival and infection risk of systemic drugs in the treatment of psoriasis  
| Paula Davila Seijo 
 
 88 
 
  
Letter to the Editor
Registries as real-world cohort studies that
are useful and necessary in the pyramid of
evidence
DOI: 10.1111/bjd.15968
DEAR EDITOR, Egeberg and Nast1 enriched us by describing the
limitations of registries in psoriasis, but focused their critical
perspective on a misguided outcome measure in ‘drug sur-
vival’. We agree that clinicians and researchers should be cau-
tious when using that proxy measure.2,3 However, the
frequent use of this poor outcome measure should not cast
doubts over all the capabilities of registries.
It is well known that methodological challenges can arise
when conducting registries as with any cohort study (e.g. lon-
gitudinal observational prospective studies).4 There are many
tools to deal with these limitations of selection bias and con-
founding such as propensity scores or inverse probability of
treatment weights.4 It should also be restated that baseline dif-
ferences confound associations only if they are associated with
the outcome. When psoriasis registries are used for their main
objective, describing safety, it is expected that few baseline
differences will cause confounding, as most of the baseline
differences are not associated with safety outcomes. Psoriasis
Area and Severity Index, mentioned by the authors, is unreli-
ably measured as there are no clearing periods between con-
secutive therapies and it is unlikely to be a confounder in
most safety outcomes. In any case, its effect can be controlled
using propensity scores, for example.
Registries, as cohorts, are useful to explore the association
between drug exposure and many long-term outcomes that
have not been explored in clinical trials. After all, many expo-
sures cannot be randomized and it is from cohort studies that
we have documented some risk factors for cardiovascular dis-
eases, many of the harmful effects of smoking, the effect of
radiation and many other medical breakthroughs. Registry data
can provide useful results and have a clear position in the
pyramid of evidence if we move away from survival studies
and follow the existing guidelines for analysing and reporting
observational studies and registry results.4,5
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Conclusions 
 
Risk of infection 
 
1. Our study showed that, in terms of infection prevention, only acitretin had a 
significantly lower adjusted risk than that of methotrexate, with methotrexate 
considered a reference for safety in terms of infections.  
2. The adjusted RR of overall infections was significantly higher in the groups 
treated with adalimumab than those treated with methotrexate, infliximab, 
ciclosporine, and ustekinumab combined with methotrexate.  
3. Ciclosporine was the only drug that showed a significantly higher risk of serious 
infections than that of methotrexate.  
4. Adalimumab in combination with methotrexate had the highest risk of infection 
recurrence.  
5. Finally, our study showed no significant change over time in the incidence rate 
of infections between patients taking methotrexate and patients taking other 
drugs or drug combinations. 
 
Drug´s survival 
6. Our study confirmed that the survival of treatment in patients with moderate-to-
severe psoriasis decreased over time for all systemic drugs included in the 
cohort, both classics and biologics.  
7. Results of survival analysis for adverse events conflict with raw and adjusted 
rates of serious adverse events, suggesting that, at least for safety, survival 
analysis is an unreliable proxy measure. 
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PSONET network 
8. Our study revealed that between country heterogeneity exists in the distribution 
of covariates, which potentially influences treatment selection.  
9. Identification of differences in the international usage of drugs can be useful for 
the interpretation of observational studies, adds knowledge and understanding of 
different health care systems, and might indicate areas for improvement of 
patient management.  
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Conclusiones: 
 
Riesgo de Infección 
1. Nuestro estudio muestra que, en términos de prevención de infecciones, solo el 
acitretino tuvo un riesgo ajustado significativamente menor que el metotrexato. 
El metotrexato puede considerarse una referencia para la seguridad en términos 
de infecciones. 
2. El riesgo relativo ajustado de las infecciones generales aumentó 
significativamente en los grupos tratados con adalimumab con metotrexato, 
infliximab, ciclosporina y ustekinumab combinados con metotrexato. 
3. La ciclosporina fue el único fármaco que mostró un riesgo significativamente 
mayor de infecciones graves en comparación con el metotrexato. 
4. Adalimumab en combinación con metotrexato tuvo el mayor riesgo de 
recurrencia de la infección. 
5. Nuestro estudio no mostró cambios significativos a lo largo del tiempo en la tasa 
de incidencia de infecciones entre pacientes que tomaban metotrexato y 
pacientes que tomaban otros fármacos o combinaciones de medicamentos. 
 
Supervivencia del tratamiento 
6. Nuestro estudio confirma que la supervivencia del tratamiento en pacientes con 
psoriasis moderada a grave disminuye con el tiempo para todos los fármacos 
sistémicos incluidos en la cohorte, tanto clásicos como biológicos. 
7. Los resultados del análisis de supervivencia para el conflicto eventos adversos 
con tasas crudas y ajustadas de eventos adversos graves sugiere que, al menos 
por seguridad, los análisis de supervivencia son una medida aproximada poco 
fiable. 
 
PSONET network 
8.  Nuestro estudio revela que existe una amplia heterogeneidad en la distribución 
de las covariables que pueden influir en la selección del tratamiento sistémico en 
psoriasis en los diferentes países que integran PSONET. 
9. La identificación de diferencias en el uso de fármacos puede ser útil para la 
interpretación de estudios observacionales, aporta conocimiento y comprensión 
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de diferentes sistemas de atención médica y podría indicar áreas para mejorar el 
manejo del paciente. 
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Infections and Psoriasis
Treatment: More “Real-World”
Data Needed with Critical Appraisal
Luigi Naldi1
Data from the Spanish registry BIOBADADERM suggest that the risks of any
infectious episode in patients treated with biologics are limited, not exceeding
the risks observed with a conventional treatment such as cyclosporine. The
registry lacked enough statistical power to analyze risks for severe infections.
These should be the focus of further research, although the difﬁculties of “real-
world” data analysis should not be trivialized.
Journal of Investigative Dermatology (2017) 137, 271e274. doi:10.1016/j.jid.2016.10.022
Da´vila-Seijo et al. (2017) present data
from the Spanish registry BIO-
BADADERM concerning the risk of in-
fections in patients treated systemically
for psoriasis. Compared with metho-
trexate, the analyses documented a
significant 71%, 58%, and 34%
increased risk of overall infections for
infliximab, cyclosporine, and eta-
nercept respectively, and a significant
40% decreased risk of infection for
acitretin. When looking at combination
therapies, there was about a 2-fold
increased risk of overall infection for
adalimumab associated with metho-
trexate and a 58% increased risk for
ustekinumab associated with metho-
trexate. Quite surprisingly, the associa-
tion of methotrexate with infliximab or
etanercept did not result in any signifi-
cant increased risk, despite the risks
documented when the latter two drugs
were used as monotherapy. When
restricting analyses to severe infection,
defined as life-threating conditions
leading to or prolonging hospitalization
or causing persistent disability or death,
a significant three times-higher risk of
infection compared with methotrexate
was observed for cyclosporine.
Nonsignificant two to three times-
higher risks were also documented for
adalimumab in association with meth-
otrexate and for infliximab alone or in
combination with methotrexate; eta-
nercept showed a nonsignificant 76%
decrease in risk. Infliximab alone and
adalimumab in combination with
methotrexate had the highest significant
risks of recurrent infection. At variance
with studies in rheumatoid arthritis,
which documented increased risks of
infection for biologics limited to the
first year of treatment, no consistent
time dependency of risk was observed.
The demand for so-called “real-
world” data on a chronic disease like
psoriasis is increasing, and this has
paralleled the introduction of new tar-
geted drugs. These drugs, which
include several biologics and, more
recently, a few small molecules, were
proven to be effective or highly effec-
tive in the context of randomized clin-
ical trials (RCTs). These RCTs typically
exclude patients with selected comor-
bidities, have restricted time spans, and
have sample sizes that are not adequate
to rule out uncommon but relevant
adverse events (e.g., those with an
incidence of less than 1 in 100).
A way of overcoming the statistical
constraints of RCTs would be to
combine them in a meta-analysis. A
meta-analysis of RCTs of biologics in
psoriasis has recently offered a reas-
suring picture concerning the risk of
severe infection (Yiu et al., 2016).
Meta-analyses cannot, however, ac-
count for the stricter patient selection
and closer monitoring criteria observed
in RCTs when compared with real-
world practice. Previous analyses of
data from the BIOBADADERM registry
documented that patients ineligible for
RCTs may represent a large proportion
of those receiving systemic therapy for
psoriasis and that these patients have
higher risk for severe adverse events.
Biologics add to a higher baseline risk
in patients who are ineligible for RCTs
(Garcia-Doval et al., 2012).
Besides the above-mentioned BIO-
BADADERM study, I am aware of only
one other published, registry-based,
cohort study assessing the risk of se-
vere infection in psoriatic patients
treated with biologics, the Psoriasis
Longitudinal Assessment and Registry
(PSOLAR). That study showed an
increased risk of serious infections for
infliximab and adalimumab but not for
other biologics when compared with a
population that had received systemic
retinoids or phototherapy (Kalb et al.,
2015). Increasing age, diabetes melli-
tus, and smoking were additional fac-
tors influencing the risk of severe
infection. Other registry-based studies
focusing on the risk of infection for bi-
ologics have considered clinical con-
ditions different from psoriasis or have
pooled data from several indications,
including psoriasis. These data may not
be representative of psoriasis, because
they have different profiles of co-
medications and different baseline
risks of infection for the conditions
under consideration.
Registries: a systematic data
collection in the real world
It is largely acknowledged that bi-
ologics are devoid, at least in the short
term, of the typical organ-specific
adverse events observed with small
molecules. On the other hand, they
may cause adverse events related to
cytokine imbalance or impaired im-
mune function (Pichler, 2006). The
resulting clinical problems, for
example, infection and/or cancer, may
be difficult to differentiate from natu-
rally occurring events, making the usual
spontaneous surveillance systems
rather inefficient at detecting relevant
1Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Department of
Dermatology, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy
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signals during the so-called post-
marketing phase. A possible exception
might be the triggering of very rare,
unusual, or dramatic adverse events
that would be more likely to prompt
reporting, such as progressive multi-
focal leukoencephalopathy occurring
with exposure to efalizumab (Nijsten
et al., 2009).
Registry-based cohort studies are one
way to overcome the limitations of
spontaneous surveillance, promoting a
proactive attitude toward the identifi-
cation of potential risks and to evaluate
treatment effectiveness. A registry could
be defined as “a systematic collection
of information on all patients with a
specific disease or other health-relevant
condition,” whereas a cohort study is “a
study where one or more samples (from
the cohort population) with different
levels of exposure to purported causal
factors (e.g., drugs) are followed over
time and assessed for the occurrence of
one or more outcomes of interest.” A
detailed overview of methods and
experience with registries evaluating
patient outcomes is prepared and
regularly updated by the Agency for
Healthcare Research and Quality of the
US Department of Health and Human
Services (Gliklich et al., 2012).
Data analysis: a path with many traps
The study of the relation between
exposure to systemic treatment for
psoriasis and infection offers a teaching
example of the hurdles and complex-
ities of the analysis of registry data
(Figure 1). At variance with randomi-
zation, which tends to balance patient
characteristics among different treat-
ment groups, clinical practice requires
that doctors adjust, as much as
possible, treatments to the needs and
characteristics of patients. As a conse-
quence, patients managed by different
treatment options in the real world may
differ at baseline for several variables
that may, unfortunately, be related to
the outcome of interest. Therefore, a
good prescribing doctor is responsible
for reducing risks and, at the same
time, confounding the comparisons
of adverse events among several
different therapies. A way to overcome
the problem, at least partly, as
reported in the BIOBADADERM article
(Da´vila-Seijo et al., 2017), is to use
propensity score analysis. A propensity
score is a statistical score that expresses
the probability of treatment assignment
conditionally on selected baseline
characteristics. It summarizes multiple
potentially confounding variables into a
single score (Moride and Abenhaim,
1994). Once the propensity score is
developed, it can be used as a weight in
a statistical model to calculate risks and
to equalize patients for variables
affecting drug prescriptions and,
possibly, outcomes. It should be noted
that a propensity score can adjust only
for confounding variables that have
been collected. If an important variable
that affects treatment assignment and
outcome is missing, then the propensity
score cannot account for it. A previous
history of infection may influence
treatment choice and outcome. In the
PSOLAR registry it was shown that a
history of significant infection before
enrollment into the registry was an in-
dependent predictor of subsequent
serious infections (Kalb et al., 2015). I
do not have information if a history of
infection before entry into the registry
was collected and analyzed within the
BIOBADADERM study.
Once patients are enrolled into a
registry, they should be followed up
over time, keeping losses to follow-up
to a minimum. One problem is the
possible preferential loss to follow-up
of those patients who experience
adverse events, a phenomenon referred
to in pharmacoepidemiology as deple-
tion of susceptibles. The resulting situ-
ation is similar to the “healthy worker
effect” observed in occupational
epidemiology, which is a tendency for
those who survive on a job (or on a
drug) to have a more favorable
morbidity experience than the refer-
ence population at large (Moride and
Abenhaim, 1994). Such an issue is
particularly important when prevalent,
rather than incident, treatment expo-
sures are considered. Prevalent expo-
sures occur when a patient is enrolled
into a registry while already on a
treatment for a period of time. In this
case, it is quite possible that treatment
survivors are more likely to be enrolled
and that some adverse events that
occurred before entry into the registry
were missed (e.g., left truncation of
survival data). It is reassuring that the
Figure 1. Selected factors affecting risk assessment of infection with exposure to drugs in a registry-
based cohort study. A summary representation of variables influencing risk evaluation being connected
with different time points in a study: entry, follow-up and outcome.
Clinical Implications
! Infections are an issue of concern when deciding about psoriasis treatment.
! The BIOBADADERM data are reassuring about the risk of any infections for
biologics.
! The risk of severe infection remains to be determined with certainty.
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BIOBADADERM study, at variance with
the PSOLAR registry previously
mentioned, considered only incident
treatments, that is, new treatments
started at the time of entry into the
registry.
A depletion of susceptibles effect in
the BIOBADADERM study might at
least partly explain the paradox of an
increased risk of infection for eta-
nercept and infliximab as monotherapy
and a lack of risk for their combination
with methotrexate. Methotrexate is
frequently added for those patients
receiving biologics who do not reach
the desired level of improvement. It
could be argued that those patients who
have experienced an adverse event,
such as infection, on a biologic drug as
monotherapy are less likely to be
considered suitable candidates for
combination treatment. As discussed in
the BIOBADADERM article, a depletion
of susceptibles effect may have also
biased risk estimates in the analysis of
recurrent infections, because patients
experiencing a first infectious episode
on a drug, if not clinically trivial, may
be offered alternative treatment
options.
When analyzing the exposure to
outcome relationship, it is important to
clearly define the time window of the
exposure, that is, the period during
which the exposure is expected to exert
its effects. The definition should be
based on pharmacokinetics and phar-
macodynamic data, and it may include
induction and latent periods. In the
BIOBADADERM study, events were
assigned to a drug if they occurred
during drug therapy or within a 90-day
period after the last dose. As an alter-
native, the time from discontinuation
plus two half-lives of each drug was
considered. The results for these two
different criteria were almost identical.
No minimum duration of exposure was
defined for the drug to produce its
effects.
Infection is an imprecise term that
includes a wide range of clinical con-
ditions, with a large spectrum of
severity levels. In the BIOBADADERM
study the reported diagnoses encom-
passed rather trivial entities such as
molluscum contagiousum and, at the
same time, severe manifestations such
as septic shock and disseminated
tuberculosis. For mild clinical manifes-
tations, the gathering of information
may be influenced by exposure and
comorbidities. Much more certain data
are recorded with severe infections.
These, however, are rare, and risk esti-
mates may suffer from a lack of statis-
tical power. In the BIOBADADERM
study, the chance of documenting a 2-
fold increase in risk, assuming an alpha
error of 5%, was much lower than 60%
for severe infections, whereas it was an
acceptable 80% when considering any
infectious episode. As a consequence,
risk estimates for severe infections were
unstable, with wide confidence in-
tervals and with obvious uncertainties
when interpreting them.
Meta-analysis of registry data
Psoriasis registries are active in several
countries, but they are heterogeneous
in terms of organization, study design,
population coverage, and methods of
data collection. It would be desirable
for these registries to communicate with
each other to harmonize procedures and
to allow comparisons of data. Even bet-
terwould be the possibility of combining
data together, especially when consid-
ering uncommon or rare events.
In Europe, several national psoriasis
registries, including the Spanish BIO-
BADADERM registry, are now collabo-
rating in a network termed the Psonet
collaboration (Table 1). In parallel with
the publication of the BIOBADADERM
article, a meta-analysis of data from
three registries contributing to Psonet
was published. They include the
Spanish registry, the Italian registry
Psocare, and the Clalit Health Service
database in Israel. The meta-analysis
focused on anti-tumor necrosis factor
drugs and compared them, pooled
together, with conventional treatment.
The analyses included a Charlson
index, that is, an index summarizing
the presence of selected comorbidities,
but not a propensity score. No docu-
mentation of increased risks for severe
infections or granulomatous infections
was documented for the anti-tumor
necrosis factor drugs when combined.
When any infectious episode, irre-
spective of severity, was considered, the
results were heterogeneous, with an
increased risk in Spain but no risk
documentation in the other two coun-
tries, probably reflecting differences in
detection and reporting among the
registries (Garcia-Doval et al., 2016).
The relationship between psoriasis
treatment and infection remains an area
in need of further research. Additional
data are required concerning severe
infections, looking at individual di-
agnoses, and assessing individual
drugs. Risk modifiers and ways to
reduce risks are additional aspects to be
explored further. All in all, the data
available suggest that current patient
selection criteria and clinical moni-
toring procedures are effective mea-
sures to minimize risks of infection in
patients treated systemically for psori-
asis and that current standards of care
should not be weakened (Chirch et al.,
2014).
CONFLICT OF INTEREST
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Table 1. Registries currently participating in the Psonet collaboration1
Country Registry Name
Austria PsoRA (Psoriasis Registry Austria)
Australia Australasian Psoriasis Registry
Czech Republic PsoREP
Denmark DermBio
France PsoBioTeq
Germany PsoBest
Israel Clalit Health Service Database
Italy Psocare, Psodit, Psoreal
Spain BIOBADADERM
Sweden PsoReg
Switzerland Swiss Dermatology Network for Biologicals SDNB
The Netherlands AMC psoriasis registry
United Kingdom BADBIR
1See also www.psonet.eu.
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Chromium(VI) Contact
Dermatitis: Getting Closer to
Understanding the Underlying
Mechanisms of Toxicity
and Sensitization!
Jeroen Buters1,2 and Tilo Biedermann3
Various haptens trigger innate immune pathways and/or induce cytotoxicity as a
part of sensitization. Adam et al. decipher in vitro the mechanisms by which
chromium(VI) induces inﬂammation, the likely prerequisites for toxicity, sensi-
tization, and allergic contact dermatitis against chromium(VI). Importantly, and
in line with other observations, chromium(VI), but not chromium(III) (or Ni(II)),
induces mitochondrial reactive oxygen species accumulation. Mitochondrial
reactive oxygen species in turn activate the NLRP3 inﬂammasome, allowing
increased IL-1b processing and secretion, which likely underlies both
chromium(VI)-induced cutaneous toxicity and sensitization. Interrupting this
mechanism, perhaps with reducing agents or inhibitors of the NLRP3/IL-1 axis,
may be a new option to prevent occupational chromium toxicity and allergy.
Journal of Investigative Dermatology (2017) 137, 274e277. doi:10.1016/j.jid.2016.11.015
Chromium toxicity and
contact dermatitis
Humans are exposed to chromium from
elemental chromium and its many
chromium salts. Chromium ions occur
in several valences, but two of these,
trivalent chromium(III) and hexavalent
chromium(VI), are of major health
concern (Bregnbak et al., 2015). Chro-
mium as the hexavalent ion (Cr(VI),
Cr6þ, chromates, dichromates) causes
the most harm (Bregnbak et al., 2015;
Nethercott et al., 1994), as it is a
known skin sensitizer and irritant.
Repeated exposure to chromium(VI)
can even result in chrome ulcers
(Bradberry and Vale, 1999; Bregnbak
et al., 2015; MAK. Chrom(VI)-
Verbindungen, 2012; Nethercott et al.,
1994). Chromium(VI) has been classi-
fied by legislative organizations as a
known human lung carcinogen (IARC,
1990; MAK. Chrom(VI)-Verbindungen,
2012).
Chromium(III) is less toxic and
evokes less skin irritation than chro-
mium(VI), and it has been believed that
this is due mainly to a lower bioavail-
ability of chromium(III), because chro-
mium(III) does not penetrate cellular
walls or skin very well (MAK.
Chrom(III), 2012; MAK. Chrom(VI)-
Verbindungen, 2012). The basis of
chromium(VI) toxicity seems to relate
to its strong oxidative capacity, which
leads to cell death. The toxicity of
chromium(III) and chromium(VI) is well
reviewed by governmental committees.
In Germany, defining the maximum
workplace concentrations has a rela-
tively long history (MAK) (IARC, 1990;
MAK. Chrom(III), 2012; MAK.
Chrom(VI)-Verbindungen, 2012).
Most human chromium exposure is
to chromium(III). Chromium(III) can
be oxidized to or is concomitantly
present in mixtures that include chro-
mium(VI). In contrast to chromium(III),
chromium(VI) penetrates the skin
easily. After penetration, chromium(VI)
is reduced by proteins or intracellular
antioxidants to chromium(III), which
then intercalates into DNA or proteins,
resulting in its effects (Bregnbak et al.,
2015; MAK. Chrom(VI)-Verbindungen,
2012). Although chromium(III) is the
mechanistic ingredient for chromium
sensitization, chromium(VI) is the bio-
logical transportable form and the
major practical problem (Figure 1).
1ZAUM—Center of Allergy and Environment, Helmholtz Center Munich/Technical University of
Munich, Member of the German Center for Lung Research (DZL), Munich, Germany; 2Ku¨hne
Foundation, Christine Ku¨hne—Center for Allergy Research and Education (CK-CARE), Davos,
Switzerland; and 3Department of Dermatology and Allergology, Technical University of Munich,
Munich, Germany
ª 2016 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.
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some outcomes over others, and better describing the overall
effect of an intervention on patient health. However, they can
be grossly misleading when component outcomes have dif-
ferent clinical importance or, as with drug persistence, even
have opposite meanings. As drug withdrawal can be due to
adverse events, improvement or lack of improvement, report-
ing a high proportion of withdrawals can represent poor or
excellent news from the perspective of patients. We simply
do not know from the concept of drug persistence. In the
study by Sbidian et al., a short survival has been attributed to
less than expected effectiveness, which is likely, but uncer-
tain.1 Drug persistence as a concept has other disadvantages,
including a lack of a clear definition, issues with intermittent
use, and influence from many external factors, such as reim-
bursement issues, the existence of alternative drugs or
changes in drug prescribing habits.5 We can be quite certain
that it is not a good measure of safety,6 and as reinforced
by Sbidian et al.,1 it is particularly poor for comparing differ-
ent drugs.
This paper has clear implications. We need to improve the
generalizability of psoriasis studies, especially of randomized
clinical trials. It is time to abandon the convenient use of drug
persistence as a proxy for safety or effectiveness in psoriasis
studies and substitute it for outcomes with an unequivocal
meaning. Finally, this paper highlights that selecting the best
drug and overall management for each psoriasis patient remain
challenging tasks to be improved.
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Targeting tryptophan transport and breakdown
in basal cell carcinoma
DOI: 10.1111/bjd.17316
Linked Article: Tina et al. Br J Dermatol 2019; 180:130–140.
Metabolism of keratinocyte cancer is an important emerging
area but under investigated, nonetheless it has important
implications for therapy, and now this new paper in this issue
of BJD addresses a potential role for tryptophan metabolism in
basal cell carcinoma (BCC).1
The essential amino acid tryptophan and its breakdown pro-
duct kynurenine are important in apoptosis inhibition,
immune suppression and the control of inflammation in a
variety of tumours, including melanoma.2,3 Tryptophan cata-
bolism to kynurenine is controlled by three dioxygenase
enzymes, tryptophan 2,3-dioxygenase (TDO), indoleamine
2,3-dioxygenase (IDO) 1 and IDO2, all of which catalyse the
same reaction in different tissues and each of which can be
specifically inhibited.2
Also important in the control of tryptophan and other
amino acids are the large neutral amino acid transporters
(LATs) solute carrier family 7 member 5 (SLC7A5/LAT1),
SLC7A7 (LAT3) and SLC7A8 (LAT2). These transporters
have a broad substrate specificity towards large neutral
amino acids (alanine, serine, threonine, cysteine, phenylala-
nine, tyrosine, leucine, isoleucine, arginine and trypto-
phan).3 SLC7A5 is the most well characterized of these
LATs and is unique in that it requires a cotransporter
SLC3A2, also known as CD98hc. SLC7A5 is upregulated in
actinic keratosis, squamous cell carcinoma and BCC,
although it was downregulated in seborrhoeic keratosis and
Bowen’s disease, suggesting that the role of this gene is
complex in keratinocyte cancer.4 The SLC3A2 knockout
mouse is protective against papilloma formation using the
standard 12-O-tetradecanoylphorbol-13-acetate (TPA)/ 7,12-
dimethylbenz[a]anthracene (DMBA) protocol,5 but it also
© 2019 British Association of DermatologistsBritish Journal of Dermatology (2019) 180, pp11–25
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LETTERS TO THE EDITOR
Comment on ‘‘Drug survival
analysis is not a good method
for assessing the safety or
effectiveness of systemic
therapies in psoriasis’’
Réplica a: ‘‘El análisis de supervivencia no es
un buen método para evaluar la seguridad o la
efectividad de los tratamientos sistémicos en
psoriasis’’
Dear Editor,
We read with great interest the article ‘‘Drug survival
analysis is not a good method for assessing the safety or
effectiveness of systemic therapies in psoriasis’’ by Davila-
Seijo and Garcia-Doval.1 In the article, the authors explain
that drug survival studies are not a good way to evaluate
the safety or effectiveness of psoriasis treatments because
biases can seriously affect the interpretation of drug survival
data. We agree with this statement but would like to add
that drug survival should be regarded as regarded as a dif-
ferent entity than a mere effectiveness or safety outcome,
and that it should be complementary to those outcomes.
Drug survival is a comprehensive measure that incorporates
effectiveness and safety as well as the preferences of both
patients and doctors. Drug survival data can easily be split
for the reason for the discontinuation (e.g., ineffectiveness
or adverse effects) to provide more detailed information.2
This does not mean that drug survival directly measures the
rate of adverse effects or the precise effectiveness of a drug.
However, it does provide important information, including
the following: (1) which adverse effects or level of inef-
fectiveness are considered unacceptable by the doctor and
patient; (2) when do adverse effects or (in)effectiveness
occur; and (3) which variables predict a sustained and suc-
cessful response to a drug.
One of the author’s main points is that drug survival is
particularly inappropriate for the comparison of drugs. How-
ever, we would like to point out that, irrespective of the
outcome (drug survival or disease activity), a control group
is actually needed for comparative effectiveness studies. In
an observational setting, confounding by (contra)indication
often plays a role in this context and is indeed problem-
atic. We believe that the real problem in these comparative
effectiveness studies the authors are referring to is not the
use of drug survival as an outcome, but the lack of a control
group or the lack of confounder correction in observational
studies.
The authors also describe certain biases that may occur
in drug survival studies. Fortunately, there are solutions that
minimize the impact of most biases, as we have described
in the Journal of Investigative Dermatology.3 Dávila-Seijo
and García-Doval mention that the authors of many stud-
ies fail to report how the end of treatment was defined,
and that defining withdrawal on the basis of the loss of
one or several doses could lead to problems when study-
ing drugs with long dosing intervals. This problem can be
solved in part by defining discontinuation as withdrawal of
the treatment for a period of more than 90 days; this is
an arbitrary but widely accepted threshold.2 The statement
that ustekinumab should be stopped 24 weeks before it can
be considered to have been discontinued does not seem valid
to us. We dealt with this problem differently, analyzing cases
of ustekinumab in which therapy had been stopped for more
than 90 days with sensitivity analyses, considering the last
injection date as well as the last injection date plus the
specific treatment interval for each case (often 12 weeks)
as the possible dates of discontinuation.3,4 The authors state
that intermittent therapy poses a problem in drug survival.
We, however, think that patients on intermittent therapy
should not be investigated using this method because the
research question in drug survival studies refers to long-term
use of treatment for chronic disease. To our knowledge,
hardly any articles on drug survival focus on intermittent
therapy. Analyzing positive events, such as disease remis-
sion, is also considered a problem. Positive events can be
analyzed when the distinction between negative and posi-
tive events is maintained at all times and the reader is made
aware of this important distinction.3 If a drug can be discon-
tinued due to both positive (e.g. remission) and negative
(e.g. ineffectiveness) events, one can censor the positive
events when one is only interested in the negative events
and vice versa.
We agree that drug survival can be influenced by
external factors, such as changes in reimbursement criteria
or the introduction of new biologics. One solution to this
problem is to restrict analyses to specific time periods.3 For
instance, in a drug survival study (adalimumab, etanercept,
ustekinumab), we chose to analyze only treatment episodes
that started after the introduction of ustekinumab, thereby
minimizing the competing risks.4 Events that lead to
withdrawal of an agent do indeed differ between pre-
scribers and patients. Therefore, a large, heterogeneous
group of prescribers and patients should be evaluated;
offering a general view of what patients and doctors accept
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from a drug in terms of safety issues and ineffectiveness.
It has been shown that large psoriasis drug survival studies
with a heterogeneous group of patients and prescribers
reported similar findings overall.5--7
To answer the question asked by these authors----‘‘Is it
really important which treatments survive longer?’’---- we do
think that drug survival is a suitable measure for analyzing
the performance of a drug in daily practice, provided the
necessary steps are taken to minimize bias.3 However, drug
survival should not be regarded as a sole outcome measure
for effectiveness or safety. It is important to use a combina-
tion of several different outcomes, each one with its specific
biases, to fully judge the performance of a drug.
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Response to the  Comment by
Van den Reek et al. on Drug
Survival Analysis is  Not a Good
Method for  Assessing the  Safety
or  Effectiveness of Systemic
Therapies in Psoriasis!
Respuesta  a la  réplica de Van den Reek et al.
a: El  análisis de  supervivencia  no es un buen
método para  evaluar la  seguridad  o la
efectividad de  los  tratamientos sistémicos en
psoriasis
Dear  Editor:
We  thank  Van  den  Reek  et al.  for their  comments  and the
opportunity  they  provide  for  further  discussion  of the  limi-
tations  of  drug  survival  analysis.  While  we  concur  with  their
enumeration  of  the problematic  aspects  of such analysis,
we  do  not  agree  with  their  assessment  of  the importance  of
those  difficulties.
Imagine  that  you  are ill  and your doctor  tells  you:  ‘‘If  you
start  taking  this drug  you have  an 80%  possibility  of  still  being
on  the  same  treatment  in twelve  months’’.  Would  you be
happy  with  that  information?  Or  would  you prefer  to  know
more  about  the  possibilities  of being  free  of  lesions  in a
year’s  time  and whether  the drug  will  cause  adverse  effects?
In  our  opinion,  drug survival  is  a  proxy  measure  that  does  not
facilitate  decision  making.  This  would  be less  important  if
the  results  of  drug  survival  analysis  and  the results  of  more
useful  proxy  measures  were  similar;  however,  at  least  on
some  occasions,  they  do  not  coincide.  Analysis  of  data  on
safety  has  revealed  discrepancies  between  the results  of
drug  survival  analysis  and  the  adverse  event  rate.1 Unfor-
tunately,  we do  not have  sufficient  comparisons  between
treatments  of  efficacy  or  effectiveness  to  check  whether
such  discrepancies  also  exist  between  the data  on drug sur-
vival  and  the  results  of  clinical  trials  and  registry  studies.
To  illustrate  the significant  limitations  of  drug survival
analysis,  we  will  comment  on  the results  of  some  of the
articles  cited  by  Van  den  Reek et al.,2--6 which  are  probably
the  most  cited  articles  on  drug survival  in  psoriasis  in the
literature.  While  those  articles  and  the letter  of  comment
from  Van  den  Reek  et  al.  propose  solutions  to  the  difficulties
involved  in  drug  survival  analyses,  the  problems  inherent  in
such  analyses  persist.
With  respect  to  how  withdrawal  of  treatment  is  defined,
2  of  the  studies  (references  4  and 5  in the  article  by  Van
den  Reek  et al.)3,4 consider  that  treatment  has  been  dis-
continued  if  the  patient  has  not received  a dose  for  more
than  90  days.  This  means  that  a  course of  treatment  with
ciclosporin  or  methotrexate  that  is  suspended  for  2 months
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and  then  restarted  does  not  count  as  withdrawal  of treat-
ment,  but  a delay  of  15  days  in the administration  of  a
dose  of  ustekinumab  represents  cessation  of  treatment.  The
authors  propose  the  use  of sensitivity  analysis  to  assess
the  effect  of  this  decision  in the  case  of  ustekinumab,  but
this  solution  does  not address  the difficulties  that  arise
in  the case  of other  drugs.  The  problem  of  the defini-
tion  used does  not disappear  with  the  application  of  this
arbitrary  criterion.  In 2  of the references  (6 and  7 in the
article  by  Van  den  Reek  et  al.),5,6 no  explanation  whatso-
ever  is  given  concerning  the definition  of  discontinuation  of
treatment.
Surprisingly,  none  of the 4  articles  cited  (4 to  7 in the
article  by  Van den  Reek et  al.)3--6 include  the possibility  of
withdrawal  due  to  a good  outcome  in  their  results.  In  our
analysis  of  the Biobadaderm  registry,1 remission  of psoriasis
was  the motive  for  discontinuation  in 27%  of  patients  and  the
motive  cited  in a further  15%  of  cases  was  ‘‘other’’.  Given
that  these  studies  are based  on  registry  data  and,  therefore,
represent  routine  clinical  practice,  such  a  large  discrepancy
(27%  in Biobadaderm  vs  0% in the other registries)  is  difficult
to  explain.  In the article  cited  by  reference  4,  the  authors
recognize  another  aspect  of the problem  of positive  and  neg-
ative  outcomes  in studies  of  drug  survival.3 They  introduce
the concept  of  happy  survival  for  patients  who  continue  on
the  treatment  and  have a Dermatology  Life  Quality Index
score  of 5  or  less.  This  proxy  represents  drug  survival  asso-
ciated  with  a positive  outcome,  in effect  reflecting  the
survival  of  treatment  due  to  remission.  However,  once  again,
the  solution  highlights  the fact  that  the  problem  persists: in
28%  of the patients  still  on  treatment  after  9  months  and in
21%  after  1 year,  the outcome  is  unhappy  survival.  How  is
this  reflected  in the  overall  data  on  drug  survival?  Is  unhappy
survival  a good  or  a  bad  outcome?
They  also  point to  the  importance  of controlling  for  con-
founding  variables,  that  is,  external  factors  associated  with
the  drug  and  the duration  of  treatment.  Three  such fac-
tors  are the interval  between  doses  of  the drug,  pricing,
and  drug  prescription  behavior.  However,  all  the  methods
we  use  to  control  confounding  variables  in observational
studies  (restriction,  stratification,  multivariate  analysis)  are
only useful  if the  confounders  can  be measured  and  when
they  affect  different  drugs.  In  drug survival  analysis,  some of
the  confounding  variables  fail  to  meet those  requirements:
there  may  be  no  overlap  across  different  treatments  of fac-
tors  related  to  pricing  and  the interval  between  doses;  and
clinicians  prescription  habits  are  difficult  to measure.  This
makes  it impossible  to  control  for  these  confounding  factors.
With  respect  to  intermittent  therapy,  the limitation  is
that  most of  the published  articles,  including  those  cited,
only  consider  one  cycle  of  treatment  per  patient  in each
analysis  and this  failure  to  consider  the data  as  a  whole  dis-
tances  the authors  from  their  ultimate  goal  of  reflecting  the
real  situation  in  clinical  practice.
We  agree  with  you that  drug survival  analysis  is  a compos-
ite  measure  of  many  factors,  but  in our  opinion  it includes
so  many  different  factors  that  the result  is  fuzzy  and dif-
ficult  to  interpret.  As  a patient,  I  would want  to  know
whether  my  condition  will  improve  and  whether  I  will expe-
rience  adverse  events;  the survival  of  the treatment  is  of
very  little  importance  to  me.  Whether  I  will still  be receiv-
ing  the  same  treatment  in  a  year’s  time  is  of interest  only
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to  the  people  selling  the  drug and those  who  are  paying
for  it.
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psoriasis, shortly after a very reassuring postmarketing 3-year
safety study report where no new side-effects were associated
with efalizumab.3,4 RCTs are designed to detect differences in
the response to therapy over short periods of treatment, but
are underpowered and too short to detect rare, serious or
long-term adverse events.
Adalimumab has now been used in clinical trials for over
20 years with over one million people worldwide currently
being treated with adalimumab across many indications. A
6000+ worldwide registry (ESPIRIT) of patients with psoriasis
on adalimumab has now published data on 7 years of treatment
with no new safety signals noted.5 This new analysis is very
reassuring with regard to the safety of adalimumab in people
with psoriasis. It must be remembered, however, that patients
in clinical trials, with strict inclusion and exclusion criteria, are
not necessarily representative of the general psoriasis popula-
tion. Those at significant risk of adverse events are often
excluded in clinical trials and so the frequency of adverse out-
comes may under-represent that of real-world patients. The use
of current carefully constructed registries that prospectively
examine the safety of biological agents in real-world settings is
essential to monitor the long-term safety of all biological agents.
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How real are ‘real-life studies’ in psoriasis,
and the uncertain meaning of drug persistence
DOI: 10.1111/bjd.17104
Linked Article: Sbidian et al. Br J Dermatol 2019; 180:86–93.
Nearly 40% of patients receiving, for the first time, a biologic
for psoriasis in France discontinue the drug within a year.1
Most of them still required medication and started a new sys-
temic drug in the following months. Sbidian et al’s finding
comes from population-based prescription data and, although
somewhat surprising, is likely to be an accurate description of
therapy in France. Results are worse if longer periods of fol-
low-up are described. In our opinion, this paper1 raises the
issues of generalizability of results in psoriasis studies and the
uncertain interpretation of drug persistence.
Psoriasis is a chronic disease, typically with a long time-
course. However, we obtain information to guide our man-
agement from selected samples followed for limited periods of
time. Generalizability refers to the extension of research find-
ings obtained from a sample population to population at large.
As discussed by the authors, recruiting selected participants in
a study can lead to results with limited application to the gen-
eral population. Explanatory randomized clinical trials are
done on highly selected populations, and some of the infer-
ences made from their results to all psoriasis patients might be
unrepresentative.2 Worryingly, this situation may be worsen-
ing.3 National registries have overcome some limitations of
studies on selected groups and are a second step in improving
generalizability. Results from this study represent a third step
of improved generalizability: they are likely to be close to
describing the whole French population of psoriasis patients
receiving systemic therapy. Likewise, it seems that results in
France are probably representative of other developed coun-
tries. Regarding drug persistence, more representative popula-
tion-based studies tend to produce more pessimistic results
than studies with a narrower selection criteria. Another source
of bias is generalizing from results of short-term clinical trials
to infer outcomes for long-term therapy.
The main outcome of this study is biologics drug persis-
tence (drug survival). Persistence can be seen as a composite
outcome consisting of several components such as drug dis-
continuation for adverse events, efficacy or other reasons.4
Composite outcomes offer advantages: reducing sample size
required for studies, avoiding the arbitrariness of selecting
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some outcomes over others, and better describing the overall
effect of an intervention on patient health. However, they can
be grossly misleading when component outcomes have dif-
ferent clinical importance or, as with drug persistence, even
have opposite meanings. As drug withdrawal can be due to
adverse events, improvement or lack of improvement, report-
ing a high proportion of withdrawals can represent poor or
excellent news from the perspective of patients. We simply
do not know from the concept of drug persistence. In the
study by Sbidian et al., a short survival has been attributed to
less than expected effectiveness, which is likely, but uncer-
tain.1 Drug persistence as a concept has other disadvantages,
including a lack of a clear definition, issues with intermittent
use, and influence from many external factors, such as reim-
bursement issues, the existence of alternative drugs or
changes in drug prescribing habits.5 We can be quite certain
that it is not a good measure of safety,6 and as reinforced
by Sbidian et al.,1 it is particularly poor for comparing differ-
ent drugs.
This paper has clear implications. We need to improve the
generalizability of psoriasis studies, especially of randomized
clinical trials. It is time to abandon the convenient use of drug
persistence as a proxy for safety or effectiveness in psoriasis
studies and substitute it for outcomes with an unequivocal
meaning. Finally, this paper highlights that selecting the best
drug and overall management for each psoriasis patient remain
challenging tasks to be improved.
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Targeting tryptophan transport and breakdown
in basal cell carcinoma
DOI: 10.1111/bjd.17316
Linked Article: Tina et al. Br J Dermatol 2019; 180:130–140.
Metabolism of keratinocyte cancer is an important emerging
area but under investigated, nonetheless it has important
implications for therapy, and now this new paper in this issue
of BJD addresses a potential role for tryptophan metabolism in
basal cell carcinoma (BCC).1
The essential amino acid tryptophan and its breakdown pro-
duct kynurenine are important in apoptosis inhibition,
immune suppression and the control of inflammation in a
variety of tumours, including melanoma.2,3 Tryptophan cata-
bolism to kynurenine is controlled by three dioxygenase
enzymes, tryptophan 2,3-dioxygenase (TDO), indoleamine
2,3-dioxygenase (IDO) 1 and IDO2, all of which catalyse the
same reaction in different tissues and each of which can be
specifically inhibited.2
Also important in the control of tryptophan and other
amino acids are the large neutral amino acid transporters
(LATs) solute carrier family 7 member 5 (SLC7A5/LAT1),
SLC7A7 (LAT3) and SLC7A8 (LAT2). These transporters
have a broad substrate specificity towards large neutral
amino acids (alanine, serine, threonine, cysteine, phenylala-
nine, tyrosine, leucine, isoleucine, arginine and trypto-
phan).3 SLC7A5 is the most well characterized of these
LATs and is unique in that it requires a cotransporter
SLC3A2, also known as CD98hc. SLC7A5 is upregulated in
actinic keratosis, squamous cell carcinoma and BCC,
although it was downregulated in seborrhoeic keratosis and
Bowen’s disease, suggesting that the role of this gene is
complex in keratinocyte cancer.4 The SLC3A2 knockout
mouse is protective against papilloma formation using the
standard 12-O-tetradecanoylphorbol-13-acetate (TPA)/ 7,12-
dimethylbenz[a]anthracene (DMBA) protocol,5 but it also
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